<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Hematol Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Hematol Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">617</journal-id><journal-id journal-id-type="pmc-domain">jhemonc</journal-id><journal-title-group><journal-title>Journal of Hematology &amp; Oncology</journal-title></journal-title-group><issn pub-type="epub">1756-8722</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8299593</article-id><article-id pub-id-type="pmcid-ver">PMC8299593.1</article-id><article-id pub-id-type="pmcaid">8299593</article-id><article-id pub-id-type="pmcaiid">8299593</article-id><article-id pub-id-type="pmid">34301270</article-id><article-id pub-id-type="doi">10.1186/s13045-021-01109-y</article-id><article-id pub-id-type="publisher-id">1109</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="CT">Christopher T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6163-3317</contrib-id><name name-style="western"><surname>Ye</surname><given-names initials="JC">J. Christine</given-names></name><address><email>jchrisye@med.umich.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution-id institution-id-type="ISNI">0000000086837370</institution-id><institution>Department of Internal Medicine, </institution><institution>University of Michigan, </institution></institution-wrap>Ann Arbor, MI 48109 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution-id institution-id-type="ISNI">0000000086837370</institution-id><institution>Rogel Cancer Center, </institution><institution>University of Michigan, </institution></institution-wrap>Ann Arbor, MI 48109 USA </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>7</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">372240</issue-id><elocation-id>115</elocation-id><history><date date-type="received"><day>7</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>07</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>28</day><month>07</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-21 16:25:26.393"><day>21</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2021</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13045_2021_Article_1109.pdf"/><abstract id="Abs1"><p id="Par1">The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient survival and advancing closer to the goal of a cure, especially in areas of immunotherapy such as chimeric antigen receptor T cells, bispecific T cell engager antibodies, antibody drug conjugates, newer generations of monoclonal antibodies, and small molecule inhibitor and modulators. This review provides an update of current myeloma therapeutics in active preclinical and early clinical development and discusses the mechanism of action of several classes of novel therapeutics.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Multiple myeloma</kwd><kwd>Review</kwd><kwd>First in human trials</kwd><kwd>Chimeric antigen receptor</kwd><kwd>CAR-T</kwd><kwd>Bispecific antibody</kwd><kwd>T cell engager</kwd><kwd>Antibody&#8211;drug conjugate</kwd><kwd>Monoclonal antibody</kwd><kwd>Small molecule inhibitor</kwd><kwd>Targeted therapy</kwd></kwd-group><funding-group><award-group><funding-source><institution>T32</institution></funding-source><award-id>T32-CA-236621</award-id><principal-award-recipient><name name-style="western"><surname>Su</surname><given-names>Christopher T.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Although multiple myeloma remains an incurable disease, the 5-year relative survival rate has nearly doubled in the last 20&#160;years, from 32.1% in 1996 to 54.9% in 2016 based on National Cancer Institute statistics. Numerous treatment options have entered the myeloma therapeutic landscape in the last 5&#8211;10&#160;years, significantly extending progression-free survival (PFS) and overall survival (OS). In addition to IMIDs (immunomodulatory agents) and PIs (proteasome inhibitors), daratumumab, an anti-CD38 antibody initially approved for relapsed/refractory patients, is now moving into the frontline setting for newly diagnosed multiple myeloma, therefore adding a third gold standard in the newly diagnosed multiple myeloma therapeutic paradigm [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par3">Relapsed/refractory multiple myeloma (RRMM) is an extremely active area of research, largely due to the nature of myeloma disease heterogeneity and clonal evolution throughout the disease progression [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Drug approvals in the last couple of years include selinexor (XOP1 nuclear export inhibitor) and isatuximab (another anti-CD38 monoclonal antibody), which were approved by the Food and Drug Administration (FDA) in July 2019 and March 2020, respectively. Most recently, attesting to the vibrancy of ongoing myeloma research, the first-in-class B-cell maturation antigen (BCMA)-targeted antibody&#8211;drug conjugate (belantamab mafodotin) was approved in August 2020 [<xref ref-type="bibr" rid="CR5">5</xref>], and&#160;BCMA-targeted CAR-T cell therapy (idecabtagene vicleucel) in March 2021 [<xref ref-type="bibr" rid="CR6">6</xref>]. Currently, the landscape of emerging multiple myeloma clinical trials is diverse and encouraging, including chimeric antigen receptor (CAR)-T cells, bispecific T-cell engager antibodies (BiTEs), antibody&#8211;drug conjugates (ADCs), newer generations of monoclonal antibodies (MoAbs) and small molecule inhibitors/modulators (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Mechanisms of action of emerging multiple myeloma therapies</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13045_2021_1109_Fig1_HTML.jpg"/></fig></p><p id="Par4">This review, as part of &#8220;First-in-human clinical trials for cancer therapy&#8221; thematic series, aims to discuss novel agents and emerging multiple myeloma therapies, with a special focus on data from early phase clinical trials presented at major 2019&#8211;2020 oncology meetings (Table <xref rid="Tab1" ref-type="table">1</xref>) and actively recruiting registered Phase 1 clinical trials (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). The number of substantially increased CAR-T trials since 2018 is especially noteworthy.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Active clinical trials of novel therapeutic agents for RRMM presented at major oncology meetings, 2019&#8211;2020</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antigen</th><th align="left" colspan="1" rowspan="1">Product name* (NCT)</th><th align="left" colspan="1" rowspan="1">Study sponsor</th><th align="left" colspan="1" rowspan="1">Estimated enrollment</th><th align="left" colspan="1" rowspan="1">Country</th><th align="left" colspan="1" rowspan="1">Clinical Update reference</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">CAR-T cells</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">JNJ-68284528 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03548207">NCT03548207</ext-link>)</td><td align="left" colspan="1" rowspan="1">Janssen</td><td align="left" colspan="1" rowspan="1">118</td><td align="left" colspan="1" rowspan="1">United States, Japan</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR7">7</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">bb21217 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03274219">NCT03274219</ext-link>)</td><td align="left" colspan="1" rowspan="1">Bluebird</td><td char="." align="left" colspan="1" rowspan="1">74</td><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR8">8</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">NY-ESO-1</td><td align="left" colspan="1" rowspan="1">GSK3377794 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03168438">NCT03168438</ext-link>)</td><td align="left" colspan="1" rowspan="1">GlaxoSmithKline</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">2019 ASH [<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA /CD19</td><td align="left" colspan="1" rowspan="1">GC012F (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04236011">NCT04236011</ext-link>)</td><td align="left" colspan="1" rowspan="1">Shanghai Changzheng Hospital</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR10">10</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA/CD38</td><td align="left" colspan="1" rowspan="1">BM 38CAR (ChiCTR1800018143)</td><td align="left" colspan="1" rowspan="1">Wuhan Tongji Medical College Union Hospital</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">2019 ASH [<xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">ALLO-715 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04093596">NCT04093596</ext-link>)</td><td align="left" colspan="1" rowspan="1">Allogene</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Bispecific antibody (BiTE)</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">Teclistamab JNJ-64007957 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03145181">NCT03145181</ext-link>)</td><td align="left" colspan="1" rowspan="1">Janssen</td><td align="left" colspan="1" rowspan="1">160</td><td align="left" colspan="1" rowspan="1">United States, the Netherlands, Spain, Sweden</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">CC-93269 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03486067">NCT03486067</ext-link>)</td><td align="left" colspan="1" rowspan="1">Celgene</td><td char="." align="left" colspan="1" rowspan="1">115</td><td align="left" colspan="1" rowspan="1">United States, Spain</td><td align="left" colspan="1" rowspan="1">2019 ASH [<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">PF-06863135 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03269136">NCT03269136</ext-link>)</td><td align="left" colspan="1" rowspan="1">Pfizer</td><td char="." align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">United States, Canada</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">TNB-383B (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03933735">NCT03933735</ext-link>)</td><td align="left" colspan="1" rowspan="1">Tenebio AbbVie</td><td char="." align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR16">16</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">REGN5458 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03761108">NCT03761108</ext-link>)</td><td align="left" colspan="1" rowspan="1">Regeneron</td><td align="left" colspan="1" rowspan="1">74</td><td align="left" colspan="1" rowspan="1">United States, Belgium</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GPRC5D&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">Talquetamab JNJ-64407564 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03399799">NCT03399799</ext-link>)</td><td align="left" colspan="1" rowspan="1">Janssen</td><td char="." align="left" colspan="1" rowspan="1">245</td><td align="left" colspan="1" rowspan="1">United States, Netherlands, Spain</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FcRH5&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">BFCR4350A (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03275103">NCT03275103</ext-link>)</td><td align="left" colspan="1" rowspan="1">Genentech</td><td char="." align="left" colspan="1" rowspan="1">300</td><td align="left" colspan="1" rowspan="1">United States, Australia, Canada, Spain</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Antibody&#8211;drug conjugate (ADC)</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA, pyrrolobenzodiazepine</td><td align="left" colspan="1" rowspan="1">MEDI2228 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03489525">NCT03489525</ext-link>)</td><td align="left" colspan="1" rowspan="1">MedImmune</td><td align="left" colspan="1" rowspan="1">142</td><td align="left" colspan="1" rowspan="1">United States, Australia, Greece</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA, Shiga-like toxin-A subunit (engineered toxin bodies)</td><td align="left" colspan="1" rowspan="1">TAK-169 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04017130">NCT04017130</ext-link>)</td><td align="left" colspan="1" rowspan="1">Millennium Takeda</td><td align="left" colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">2019 ASH [<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Monoclonal antibody (MoAb)</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">CD38</td><td align="left" colspan="1" rowspan="1">TAK-079 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03439280">NCT03439280</ext-link>)</td><td align="left" colspan="1" rowspan="1">Millennium Takeda</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">2020 ASCO [<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CD38 with interferon</td><td align="left" colspan="1" rowspan="1">TAK-573 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03215030">NCT03215030</ext-link>)</td><td align="left" colspan="1" rowspan="1">Millennium Takeda</td><td align="left" colspan="1" rowspan="1">151</td><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CD38</td><td align="left" colspan="1" rowspan="1">SAR442085 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04000282">NCT04000282</ext-link>)</td><td align="left" colspan="1" rowspan="1">Sanofi</td><td align="left" colspan="1" rowspan="1">78</td><td align="left" colspan="1" rowspan="1">United States, France, Spain</td><td align="left" colspan="1" rowspan="1">2020 AACR[<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Small molecule inhibitors and modulators</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCL-2 inhibitor</td><td align="left" colspan="1" rowspan="1">Venetoclax (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03314181">NCT03314181</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01794520">NCT01794520</ext-link>)</td><td align="left" colspan="1" rowspan="1">AbbVie</td><td char="." align="left" colspan="1" rowspan="1">104, 117</td><td align="left" colspan="1" rowspan="1">United States, Australia, Belgium, Canada, Denmark, France, Germany, Norway</td><td align="left" colspan="1" rowspan="1">2019 ASH [<xref ref-type="bibr" rid="CR25">25</xref>], 2019 ASH [<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BCL-2 inhibitor</td><td align="left" colspan="1" rowspan="1">AT-101 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02697344">NCT02697344</ext-link>)</td><td align="left" colspan="1" rowspan="1">Mayo Clinic</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">2019 ASH [<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">HDAC inhibitor</td><td align="left" colspan="1" rowspan="1">Alteminostat (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03150316">NCT03150316</ext-link>)</td><td align="left" colspan="1" rowspan="1">Chong Kun Dang Pharamaceutical</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">South Korea</td><td align="left" colspan="1" rowspan="1">2019 ASH [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">HDAC inhibitor</td><td align="left" colspan="1" rowspan="1">Chidamide (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04025450">NCT04025450</ext-link>)</td><td align="left" colspan="1" rowspan="1">The First Affiliated Hospital of Soochow University</td><td char="." align="char" colspan="1" rowspan="1">50 (high-risk NDMM)</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">2019 ASH [<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cereblon E3 ligase modulator</td><td align="left" colspan="1" rowspan="1">Iberdomide (CC-220) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02773030">NCT02773030</ext-link>)</td><td align="left" colspan="1" rowspan="1">Celgene</td><td char="." align="left" colspan="1" rowspan="1">449</td><td align="left" colspan="1" rowspan="1">United States, France, Germany, Italy, Japan, the Netherlands, Spain, United Kingdom</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cereblon E3 ligase modulator</td><td align="left" colspan="1" rowspan="1">CC-92480 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03374085">NCT03374085</ext-link>)</td><td align="left" colspan="1" rowspan="1">Celgene</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">United States, Canada, Denmark, Finland, Spain, United Kingdom</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MEK inhibitor</td><td align="left" colspan="1" rowspan="1">Cobimetinib (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03312530">NCT03312530</ext-link>)</td><td align="left" colspan="1" rowspan="1">Hoffmann-La Roche</td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">Czechia, Denmark, France, Germany, Netherlands, Norway, Poland, Spain, Sweden</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MEK and BRAF inhibitors</td><td align="left" colspan="1" rowspan="1">Encorafenib and binimetinib (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02834364">NCT02834364</ext-link>)</td><td align="left" colspan="1" rowspan="1">University of Heidelberg</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Germany</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Other therapies</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Peptidase enhanced cytotoxic</td><td align="left" colspan="1" rowspan="1">Melflufen (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03481556">NCT03481556</ext-link>)</td><td align="left" colspan="1" rowspan="1">Oncopeptides</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">United States, Czechia, Spain</td><td align="left" colspan="1" rowspan="1">2020 ASH [<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Peptidase enhanced cytotoxic</td><td align="left" colspan="1" rowspan="1">Melflufen (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02963493">NCT02963493</ext-link>)</td><td align="left" colspan="1" rowspan="1">Oncopeptides</td><td align="left" colspan="1" rowspan="1">157</td><td align="left" colspan="1" rowspan="1">United States, France, Italy, Spain</td><td align="left" colspan="1" rowspan="1">2020 ASCO [<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ASCO</italic> American Society of Clinical Oncology, <italic toggle="yes">ASH</italic> American Society of Hematology, <italic toggle="yes">AACR</italic> American Association for Cancer Research</p><p>*In cases where no unique product name was given, only the NCT number is listed to the bottom of the table (see Table <xref rid="Tab2" ref-type="table">2</xref> for example)</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Phase 1 trials by year and type of studies, 2010&#8211;2020. <italic toggle="yes">ADC</italic> antibody&#8211;drug conjugate, <italic toggle="yes">BiTE</italic> bispecific antibody, <italic toggle="yes">CAR-T</italic> chimeric antigen receptor T cell, <italic toggle="yes">MoAb</italic> monoclonal antibody, <italic toggle="yes">Small</italic> small molecule inhibitor/modulator. Therapies not categorized as one of the above were excluded (59/363, 16%)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13045_2021_1109_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec2"><title>Chimeric antigen receptor (CAR)-T cell</title><p id="Par5">CAR-T therapy revolutionized immunotherapy in myeloma treatment since autologous stem cell transplant (ASCT) [<xref ref-type="bibr" rid="CR36">36</xref>]. CAR-T therapy can be broadly grouped into three groups: single-target, multi-target, and universal CAR-T (Table <xref rid="Tab2" ref-type="table">2</xref>). The ideal therapeutic CAR-T targets a cell surface antigen that is preferentially, and ideally exclusively, expressed on myeloma cells [<xref ref-type="bibr" rid="CR37">37</xref>]. Resistance mechanisms such as &#8220;on target off tumor&#8221; recognition (expression of targeted antigens on normal cells) and &#8220;antigen escape&#8221; (loss of targeted antigens on tumor cells) pose ongoing therapeutic challenges in CAR-T therapy [<xref ref-type="bibr" rid="CR38">38</xref>]. As a result, dual-target CAR-T strategies to increase precision of targeting have been proposed. Single-target CAR-T cells express one extracellular single-chain variable fragment recognizing tumor antigens, while dual-target CAR-T cells utilize co-stimulatory receptor design (separating the T-cell activation domain and the co-stimulatory domain into two separate CARs) or tandem CARs (two tandem-linked antigen recognition moieties coupled with one activation domain) [<xref ref-type="bibr" rid="CR39">39</xref>]. Cytokine release syndrome (CRS) and neurotoxicity are significant adverse effects and important considerations for cellular-directed therapy (CAR-T and BiTE). These toxicities along with associated overall response rates for the treatments discussed are summarized in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Phase 1 and early phase 1 CAR-T trials for RRMM, as of December 31, 2020, with study start date after January 1, 2019</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antigen</th><th align="left" colspan="1" rowspan="1">Product name* (NCT)</th><th align="left" colspan="1" rowspan="1">Study sponsor</th><th align="left" colspan="1" rowspan="1">Estimated enrollment</th><th align="left" colspan="1" rowspan="1">Country</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Single-target CAR-T cells</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">IM21 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04537442">NCT04537442</ext-link>)</td><td align="left" colspan="1" rowspan="1">Beijing Immunochina Medical Science and Technology</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">CT053 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03975907">NCT03975907</ext-link>)</td><td align="left" colspan="1" rowspan="1">Carsgen</td><td align="left" colspan="1" rowspan="1">62</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04271644">NCT04271644</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04272151">NCT04272151</ext-link></td><td align="left" colspan="1" rowspan="1">Chongqing Precision Biotech</td><td align="left" colspan="1" rowspan="1"><p>80</p><p>40</p></td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">C-CAR088 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03815383">NCT03815383</ext-link>)</td><td align="left" colspan="1" rowspan="1">First Affiliated Hospital with Nanjing Medical University</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04626752">NCT04626752</ext-link></td><td align="left" colspan="1" rowspan="1">Hebei Senlang Biotechnology</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">C-CAR088 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03751293">NCT03751293</ext-link>)</td><td align="left" colspan="1" rowspan="1">Hebei Yanda Ludaopei Hospital</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04601935">NCT04601935</ext-link></td><td align="left" colspan="1" rowspan="1">Nanjing Legend Biotech</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">C-CAR088 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04295018">NCT04295018</ext-link>)</td><td align="left" colspan="1" rowspan="1">Peking Union Medical College Hospital</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04186052">NCT04186052</ext-link></td><td align="left" colspan="1" rowspan="1">PersonGen Bio (Suzhou)</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">C-CAR088 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04322292">NCT04322292</ext-link>)</td><td align="left" colspan="1" rowspan="1">Tianjing Institute of Hematology and Blood Diseases</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04637269">NCT04637269</ext-link></td><td align="left" colspan="1" rowspan="1">Xinqiao Hospital of Chongqing</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">CARTBCMA ARI0002h (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04309981">NCT04309981</ext-link>)</td><td align="left" colspan="1" rowspan="1">Institut d'Investigacions Biom&#232;diques August Pi i Sunyer</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">Spain</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04155749">NCT04155749</ext-link></td><td align="left" colspan="1" rowspan="1">Arcelix</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">CT053 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03915184">NCT03915184</ext-link>)</td><td align="left" colspan="1" rowspan="1">Carsgen</td><td align="left" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">United States, Canada</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">Descartes-11 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03994705">NCT03994705</ext-link>)</td><td align="left" colspan="1" rowspan="1">Cartesian</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">CYAD-211 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04613557">NCT04613557</ext-link>)</td><td align="left" colspan="1" rowspan="1">Celyad Oncology</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">United States, Belgium</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">CC-98633 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04394650">NCT04394650</ext-link>)</td><td align="left" colspan="1" rowspan="1">Juno/Celgene</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">PHE885 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04318327">NCT04318327</ext-link>)</td><td align="left" colspan="1" rowspan="1">Novartis</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">CD4</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04162340">NCT04162340</ext-link></td><td align="left" colspan="1" rowspan="1">iCell Gene Therapeutics</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">CD22</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03999697">NCT03999697</ext-link></td><td align="left" colspan="1" rowspan="1">PersonGen BioTherapeutics (Suzhou)</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">CD44</td><td align="left" colspan="1" rowspan="1">MLM-CAR44.1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04097301">NCT04097301</ext-link>)</td><td align="left" colspan="1" rowspan="1">MolMed S.p.A</td><td align="left" colspan="1" rowspan="1">58</td><td align="left" colspan="1" rowspan="1">Italy</td></tr><tr><td align="left" colspan="1" rowspan="1">CD138</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03672318">NCT03672318</ext-link></td><td align="left" colspan="1" rowspan="1">University of North Carolina</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">GPRC5D</td><td align="left" colspan="1" rowspan="1">MCARH109 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04555551">NCT04555551</ext-link>)</td><td align="left" colspan="1" rowspan="1">Memorial Sloan Kettering Medical Center</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">HA-1</td><td align="left" colspan="1" rowspan="1">MDG1021 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04464889">NCT04464889</ext-link>)</td><td align="left" colspan="1" rowspan="1">Medigene</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">The Netherlands</td></tr><tr><td align="left" colspan="1" rowspan="1">SLAMF7</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04499339">NCT04499339</ext-link></td><td align="left" colspan="1" rowspan="1">Wuerzburg University Hospital</td><td align="left" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">Germany</td></tr><tr><td align="left" colspan="1" rowspan="1">SLAMF7</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03958656">NCT03958656</ext-link></td><td align="left" colspan="1" rowspan="1">National Cancer Institute</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">TnMUC1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04025216">NCT04025216</ext-link></td><td align="left" colspan="1" rowspan="1">Tmunity</td><td align="left" colspan="1" rowspan="1">112</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Dual-target CAR-T cells</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA CD19</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04194931">NCT04194931</ext-link></td><td align="left" colspan="1" rowspan="1">The First Affiliated Hospital of Nanchang University</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA CD19</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04162353">NCT04162353</ext-link></td><td align="left" colspan="1" rowspan="1">iCell Gene Therapeutics</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA CD19</td><td align="left" colspan="1" rowspan="1">GC012F (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04236011">NCT04236011</ext-link>)</td><td align="left" colspan="1" rowspan="1">Shanghai Changzheng Hospital</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA CD19</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04280328">NCT04280328</ext-link></td><td align="left" colspan="1" rowspan="1">Xian Xijing Hospital</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA CD19</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04603872">NCT04603872</ext-link></td><td align="left" colspan="1" rowspan="1">Zhejiang University</td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Universal CAR-T cells</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">ALLO-715 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04093596">NCT04093596</ext-link>)</td><td align="left" colspan="1" rowspan="1">Allogene</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">CTX120 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04244656">NCT04244656</ext-link>)</td><td align="left" colspan="1" rowspan="1">CRISPR Therapeutics</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">United States, Australia, Spain</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">PBCAR269A (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04171843">NCT04171843</ext-link>)</td><td align="left" colspan="1" rowspan="1">Precision BioSciences</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Other</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Anti-BCMA CAR-NK cells</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03940833">NCT03940833</ext-link></td><td align="left" colspan="1" rowspan="1">Asclepius Technology (Suzhou)</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">PD-L1 plus other antigen</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04191941">NCT04191941</ext-link></td><td align="left" colspan="1" rowspan="1">Timmune Biotech</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">CD34&#8201;+&#8201;enriched hematopoietic progenitor cells expressing interferon-&#593;2</td><td align="left" colspan="1" rowspan="1">Temferon (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03875495">NCT03875495</ext-link>)</td><td align="left" colspan="1" rowspan="1">Genenta</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Italy</td></tr><tr><td align="left" colspan="1" rowspan="1">CD8&#8201;+&#8201;T-cells expressing WT1, CD138, NY-ESO-1, and CS1</td><td align="left" colspan="1" rowspan="1">NEXI-002 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04505813">NCT04505813</ext-link>)</td><td align="left" colspan="1" rowspan="1">NexImmune</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">United States</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup> In cases where no unique product name was given, only the NCT number is listed</p></table-wrap-foot></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Overall response rates, cytokine release syndrome, and neurotoxicity associated with selected cellular-directed therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antigen</th><th align="left" colspan="1" rowspan="1">Product name (NCT)</th><th align="left" colspan="1" rowspan="1">Study enrollment (n)</th><th align="left" colspan="1" rowspan="1">Median time to follow-up (months)</th><th align="left" colspan="1" rowspan="1">Overall response rate (%)</th><th align="left" colspan="1" rowspan="1">Cytokine release syndrome (%)</th><th align="left" colspan="1" rowspan="1">Neurotoxicity (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">CAR-T cells</italic></td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">JNJ-68284528 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03548207">NCT03548207</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">97</td><td align="left" colspan="1" rowspan="1">8.8</td><td align="left" colspan="1" rowspan="1">95</td><td align="left" colspan="1" rowspan="1">95</td><td align="left" colspan="1" rowspan="1">21</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">bb21217 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03274219">NCT03274219</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">8.5</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">67</td><td align="left" colspan="1" rowspan="1">22</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA /CD19</td><td align="left" colspan="1" rowspan="1">GC012F (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04236011">NCT04236011</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">7.3</td><td align="left" colspan="1" rowspan="1">94</td><td align="left" colspan="1" rowspan="1">88</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA/CD38</td><td align="left" colspan="1" rowspan="1">BM 38CAR (ChiCTR1800018143)</td><td char="." align="char" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">9.0</td><td align="left" colspan="1" rowspan="1">87.5</td><td align="left" colspan="1" rowspan="1">62.5</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA</td><td align="left" colspan="1" rowspan="1">ALLO-715 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04093596">NCT04093596</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">2.0</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Bispecific antibody (BiTE)</italic></td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">Teclistamab JNJ-64007957 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03145181">NCT03145181</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">128</td><td align="left" colspan="1" rowspan="1">n/a</td><td align="left" colspan="1" rowspan="1">64</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">5</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">CC-93269 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03486067">NCT03486067</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">3.7</td><td align="left" colspan="1" rowspan="1">83.3</td><td align="left" colspan="1" rowspan="1">89.5</td><td align="left" colspan="1" rowspan="1">n/a</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">PF-06863135 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03269136">NCT03269136</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">n/a</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">61</td><td align="left" colspan="1" rowspan="1">n/a</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">TNB-383B (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03933735">NCT03933735</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">n/a</td><td align="left" colspan="1" rowspan="1">37</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">13 (headache)</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">REGN5458 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03761108">NCT03761108</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">2.4</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1">GPRC5D&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">Talquetamab JNJ-64407564 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03399799">NCT03399799</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">137</td><td align="left" colspan="1" rowspan="1">n/a</td><td align="left" colspan="1" rowspan="1">78</td><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">5</td></tr><tr><td align="left" colspan="1" rowspan="1">FcRH5&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">BFCR4350A (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03275103">NCT03275103</ext-link>)</td><td char="." align="char" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">6.2</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">n/a</td></tr></tbody></table></table-wrap></p><sec id="Sec3"><title>Single-target CAR-T</title><p id="Par6">Although there are numerous CAR-T candidates in clinical trials, only one CAR-T product is approved for clinical use in multiple myeloma. The most common cellular target in multiple myeloma CAR-T therapies currently is BCMA, a transmembrane glycoprotein in the tumor necrosis factor superfamily which is critical for B-cell differentiation to plasma cells and long-term plasma cell survival [<xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR42">42</xref>]. Furthermore, BCMA is preferentially expressed on plasma cells and not normal human tissue, including primary human CD34+ hematopoietic cells, making it an attractive target for CAR-T therapy [<xref ref-type="bibr" rid="CR43">43</xref>]. The CAR-T candidate which has currently advanced the furthest in clinical development is idecabtagene vicleucel, a&#160;recent FDA-approved BCMA-directed CAR-T, that&#160;reported a 73% overall response rate (ORR) and minimal residual disease (MRD) negativity rate of 26% in relapsed refractory myeloma patients [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par7">The LEGEND-2 trial (LCAR-B38M, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03090659">NCT03090659</ext-link>, Phase 1, China) utilized a CAR-T design that incorporates two BCMA-targeting single-domain antibodies and one 4-1BB co-stimulatory domain It has enrolled 57 RRMM patients treated with at least 3 prior lines of therapy at four different sites with different conditioning regimens and number of CAR-T cells administered [<xref ref-type="bibr" rid="CR44">44</xref>]. ORR was 88%, with CR achieved by 74% of evaluable patients (of which 93% achieved MRD-negativity). Median OS is not yet reached (at follow-up of 19&#160;months), with OS at 18-months being 68%. Median PFS was 20&#160;months for all patients, and 28&#160;months for MRD-negative patients. Most common AEs were pyrexia (91%), CRS (90%, of which 82% were grade 1&#8211;2), leukopenia (30%), and thrombocytopenia (23%).</p><p id="Par8">The CARTITUDE-1 trial (JNJ-4528, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03548207">NCT03548207</ext-link>, Phase 1b, United States and Japan) has enrolled 97 RRMM patients treated with median 6 prior lines of therapy [<xref ref-type="bibr" rid="CR7">7</xref>]. This study utilized&#160;the same CAR-T construct as in LEGEND-2 trial. Cyclophosphamide and fludarabine (Cy/Flu) was used as the conditioning regimen. ORR was 95% at median follow-up of 8.8&#160;months, with 56% stringent complete responses (sCR) in evaluable patients. Median time to first response was 1.0&#160;months, and median duration of response has not been reached. The 6-month PFS and overall survival (OS) rates were 87% and 94%, respectively. Most common AEs were CRS (95%, of which 96% were grade 1&#8211;2), neutropenia (91%), and anemia (81%). The rate of neurotoxicity was 21%, of which 90% were grade 1&#8211;2.</p><p id="Par9">The CRB-402 trial (bb21217, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03274219">NCT03274219</ext-link>, Phase 1, United States) has enrolled 46 RRMM patients treated with median 6 prior lines of therapy [<xref ref-type="bibr" rid="CR8">8</xref>]. The study utilized a CAR-T construct based on idecabtagene vicleucel, consisting of one anti-BCMA single-chain variable fragment with one intracellular 4-1BB co-stimulatory domain [<xref ref-type="bibr" rid="CR45">45</xref>]. Cy/Flu was used as the conditioning regimen. Clinical response was seen in 55% of evaluable patients with median follow-up time of 8.5&#160;months. Median time to CR was 2.5&#160;months and duration of response 11.9&#160;months. AEs reported were CRS (67%, of which 94% were grade 1&#8211;2) and neurotoxicity (22%, of which 70% were grade 1&#8211;2). The CRB-401 trial (bb2121, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02658929">NCT02658929</ext-link>, Phase 1, United States), which uses the same CAR-T construct as bb21217 but lacks the PI3K inhibitor bb007 added to bb21217 during ex vivo culture, similarly demonstrated efficacy and safety with median follow-up of 14.7&#160;months and ORR of 76% in evaluable patients [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par10">Other antigens most recently being explored for single-target CAR-T include CD4, CD22, CD44, CD138, HA-1, SLAMF7/CS1, TnMUC1 (Table <xref rid="Tab2" ref-type="table">2</xref>), among others including CD19, CD38, NY-ESO-1, and numerous others described in literature [<xref ref-type="bibr" rid="CR47">47</xref>]. The challenge to implement these differing antigen approaches is optimizing on-tumor targeting while minimizing toxic effects to normal tissue due to co-expression of myeloma markers. The NY-ESO-1 TCR T trial (GSK3377794, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03168438">NCT03168438</ext-link>, Phase 1, United States) employs CAR-T targeted against NY-ESO-1, a cancer antigen expressed in diverse tumor types, including multiple myeloma [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Although only three patients were dosed with the trial medication at time of report, the authors report a 57% rate of positivity in bone marrow samples for NY-ESO-1 in eligible RRMM patients, suggesting NY-ESO-1 targeting may be a viable novel avenue of approach.</p></sec><sec id="Sec4"><title>Dual-target CAR-T</title><p id="Par11">Several dual-target CAR-T trials have recently begun recruitment. All focus on BCMA and CD19 co-expressing CAR-Ts, which has demonstrated significant in vitro cytolytic activity on dual-expressor cells leading to complete tumor remission greater than that of BCMA or CD19 CAR-T alone [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par12">The GC012F trial (GC012F, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04236011">NCT04236011</ext-link>, Phase 1, China) enrolled 16 RRMM patients treated with median 5 prior lines of therapy [<xref ref-type="bibr" rid="CR10">10</xref>]. The study used a dual-target CAR constructed by linking BCMA and CD19 single-chain variable fragments and Cy/Flu was used as the conditioning regimen. ORR was reported as 94% in evaluable patients, with 56% reaching MRD-negative sCR at median follow-up time of 7.3&#160;months. CRS occurred in 88% of patients, of which 88% were grade 1&#8211;2. No neurotoxicity was observed.</p><p id="Par13">The BM38 CAR trial (BM38 CAR, ChiCTR1800018143, Phase 1, China) enrolled 16 RRMM patients treated with at least 2 prior lines of therapy [<xref ref-type="bibr" rid="CR11">11</xref>]. The study employed a dual-target CAR incorporating anti-CD38 and anti-BCMA antigen-recognition single-chain variable fragments linked in tandem to increase on-target sensitivity. Cy/Flu was used as the conditioning regimen. ORR was reported as 87.5% in evaluable patients, with 50% reaching sCR. Median PFS still has not been reached, but PFS at 9&#160;months was 75%. The authors report CRS occurring in 62.5% of patients (60% had grade 1&#8211;2, while others had higher grades requiring tocilizumab). No dose limiting toxicities or neurotoxicity at levels higher than grade 3 were reported by the study authors at median follow-up of 36&#160;weeks.</p></sec><sec id="Sec5"><title>Universal CAR-T/NK</title><p id="Par14">All CAR-T therapies discussed thus far are autologous in origin, which pose advantages such as long-term persistence of engineered T cells due to the lack of an allogeneic reaction. However, autologous CAR-T therapy must be opportunely coordinated from harvesting to manufacturing and to final infusion. Some patients may not be able to afford the wait time of an additional 1&#8211;2&#160;months due to rapid disease progression. Furthermore, previous lines of therapy that may negatively impact autologous T cells and T cell dysfunction are considerations following immunosuppression in the myeloma microenvironment [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Thus, universal CAR-T/NK (UCAR-T/NK) therapy has been proposed as a treatment strategy to address these challenges, with advantages including batch-production and &#8220;off the shelf&#8221; availability and healthy T cells, but disadvantages including increased risk of graft-versus-host disease (GvHD) [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par15">The feasibility of UCAR-T was described in an ex vivo platform which used bulk bone marrow biopsies from newly-diagnosed multiple myeloma (NDMM) and RRMM patients with high risk cytogenetics [<xref ref-type="bibr" rid="CR53">53</xref>]. Following co-culture, young healthy donor anti-BCMA CAR-T cells against primary MM cells were able to achieve a specific anti-BCMA CAR-T cell killing rate of 13&#8211;73% while keeping target effects directed away from non-tumor cells. However, associated in vivo toxicity remains to be seen.</p><p id="Par16">The ALLO-715 trial (ALLO-715, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04093596">NCT04093596</ext-link>, Phase 1, United States) reported the first UCAR-T results, enrolling 19 RRMM patients treated with median 5 lines of prior therapy [<xref ref-type="bibr" rid="CR12">12</xref>]. The study employed anti-BCMA UCAR-T cells with optimization to reduce the risk of GvHD and promote selective prolonged host lymphodepletion. Different conditioning regimens were used in treatment arms. ORR was reported as 60% in the arm with the highest efficacy, with 1 reaching sCR and all responders reached at least very good partial response (VGPR) and MRD-negativity. The most common AEs greater than grade 3 were anemia (41%), neutropenia (41%), and lymphopenia (29%). One grade 5 AE was reported as a sequela of multifocal pneumonia related to the conditioning regimen. No neurotoxicity or GvHD has yet been seen, with CRS reported in 24% of patients (75% grade 1, 25% grade 2).</p><p id="Par17">Among ongoing UCAR-T trials, the CRISPR-Cas9 platform is being explored for the new generation of CAR-T cells, as the gene editing system is able to construct UCAR-T cells with defective T cell receptors and class I major histocompatibility complexes, avoiding GvHD and rapid rejection of the host immune system due to these modifications [<xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par18">Furthermore, universal natural killer (NK) cell therapy is also being developed, although therapeutic challenges include specificity, persistence after infusion, and in vivo maximal activity of donor NK products. Phase 1 data of GDA-201 on 15 RRMM patients concurrently receiving elotuzumab showed no dose limiting toxicities and transient adverse effects without neurotoxicity, CRS, or GvHD. Response rate data has not been reported for myeloma patients, although the universal NK cell product demonstrated significant activity against multiple-refractory non-Hodgkin&#8217;s lymphoma with ORR of 73% [<xref ref-type="bibr" rid="CR55">55</xref>].</p></sec></sec><sec id="Sec6"><title>Bispecific T-cell engager antibodies (BiTEs)</title><p id="Par19">Bispecific T-cell engager antibodies (BiTEs), the new kids on the block, comprise another important class of immunotherapies being explored in RRMM. Blinatumomab, an anti-CD19 BiTE for relapsed/refractory B-cell precursor acute lymphoblastic leukemia, was the first to be approved for clinical use in 2014 [<xref ref-type="bibr" rid="CR56">56</xref>]. These constructs bind concomitantly to T cells and malignant cells, directing the cytotoxic effect of T cells selectively against tumor cells. Thus, BiTEs mimic CAR-T cells in mechanism and activity, although they do not require an extensive manufacturing process of viral transduction or donor T cell harvest. BiTEs join two single-chain variable fragments in tandem via a linker/connector [<xref ref-type="bibr" rid="CR57">57</xref>]. An alternative DuoBody system is being developed, which utilizes a controlled antigen-binding fragment (Fab) arm exchange of IgG antibodies to create a new bispecific IgG [<xref ref-type="bibr" rid="CR58">58</xref>]. Although several BiTE constructs are under investigation, none have yet been approved for clinical use for multiple myeloma. Numerous proposed trials from the last 2&#160;years are currently in progress (Table <xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Phase 1 and early phase 1 bispecific antibodies (BiTE), antibody&#8211;drug conjugates (ADC), and monoclonal antibodies (MoAb) for RRMM, as of December 31, 2020, with study start date after January 1, 2019</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Target antigens</th><th align="left" colspan="1" rowspan="1">Product name (NCT)</th><th align="left" colspan="1" rowspan="1">Study sponsor</th><th align="left" colspan="1" rowspan="1">Estimated enrollment</th><th align="left" colspan="1" rowspan="1">Country</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Bispecific antibodies (BiTE)</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">REGN5459 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04083534">NCT04083534</ext-link>)</td><td align="left" colspan="1" rowspan="1">Regeneron</td><td char="." align="char" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">TNB-383B (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03933735">NCT03933735</ext-link>)</td><td align="left" colspan="1" rowspan="1">Teneobio</td><td char="." align="char" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD3&#8201;&#215;&#8201;albumin (&#8220;tri-specific&#8221;)</td><td align="left" colspan="1" rowspan="1">HPN217 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04184050">NCT04184050</ext-link>)</td><td align="left" colspan="1" rowspan="1">Harpoon</td><td char="." align="char" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA&#8201;&#215;&#8201;CD16a</td><td align="left" colspan="1" rowspan="1">RO7297089 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04434469">NCT04434469</ext-link>)</td><td align="left" colspan="1" rowspan="1">Genentech</td><td char="." align="char" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">Australia, Denmark, Norway</td></tr><tr><td align="left" colspan="1" rowspan="1">CD28/38&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">SAR442257 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04401020">NCT04401020</ext-link>)</td><td align="left" colspan="1" rowspan="1">Sanofi</td><td char="." align="char" colspan="1" rowspan="1">57</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">GPRC5D&#8201;&#215;&#8201;CD3 and BCMA&#8201;&#215;&#8201;CD3</td><td align="left" colspan="1" rowspan="1">Talquetamab and teclistamab (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04108195">NCT04108195</ext-link>)</td><td align="left" colspan="1" rowspan="1">Janssen</td><td char="." align="char" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">United States, Canada, Germany, the Netherlands, Spain</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Antibody&#8211;drug conjugates (ADC)</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BCMA, monomethyl auristatin-F [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left" colspan="1" rowspan="1">GSK2857916 (belantamab mafodotin) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03828292">NCT03828292</ext-link>)</td><td align="left" colspan="1" rowspan="1">GlaxoSmithKline</td><td char="." align="char" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Japan</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA, maytansinoid</td><td align="left" colspan="1" rowspan="1">CC-99712 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04036461">NCT04036461</ext-link>)</td><td align="left" colspan="1" rowspan="1">Celgene</td><td char="." align="char" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">United States, Canada</td></tr><tr><td align="left" colspan="1" rowspan="1">BCMA, Shiga-like toxin-A subunit (engineered toxin bodies) [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left" colspan="1" rowspan="1">TAK-169 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04017130">NCT04017130</ext-link>)</td><td align="left" colspan="1" rowspan="1">Millennium Takeda</td><td char="." align="char" colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">CD46, monomethyl auristatin-F [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left" colspan="1" rowspan="1">FOR46 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03650491">NCT03650491</ext-link>)</td><td align="left" colspan="1" rowspan="1">Fortis</td><td char="." align="char" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Monoclonal antibodies (MoAb)</italic></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">CD38</td><td align="left" colspan="1" rowspan="1">SAR442085 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04000282">NCT04000282</ext-link>)</td><td align="left" colspan="1" rowspan="1">Sanofi</td><td char="." align="char" colspan="1" rowspan="1">78</td><td align="left" colspan="1" rowspan="1">United States, France, Spain</td></tr><tr><td align="left" colspan="1" rowspan="1">CD47</td><td align="left" colspan="1" rowspan="1">AO-176 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445701">NCT04445701</ext-link>)</td><td align="left" colspan="1" rowspan="1">Arch Oncology</td><td char="." align="char" colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-18</td><td align="left" colspan="1" rowspan="1">AEVI-007 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04671251">NCT04671251</ext-link>)</td><td align="left" colspan="1" rowspan="1">Aevi/Cerecor</td><td char="." align="char" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">United States</td></tr></tbody></table></table-wrap></p><p id="Par20">Teclistamab is a DuoBody bispecific BCMA and CD3 antibody which can be administered both intravenously and subcutaneously. The teclistamab trial (JNJ-64007957, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03145181">NCT03145181</ext-link>, Phase 1, multiple countries) has enrolled 128 RRMM patients treated with median 6 prior lines of therapy in a dose-finding trial [<xref ref-type="bibr" rid="CR13">13</xref>]. A response rate of 64% was achieved by all evaluable patients. Median time to first response was 1&#160;month, and median duration of response was not reached, with responding patients remaining on therapy from 2 to 21&#160;months. Most common AEs were anemia (55%), neutropenia (55%), and CRS (53%, all grade 1&#8211;2). Grade 3&#8211;4 AEs were reported by 39% of patients, with the most common being neutropenia (23%) and anemia (9%). Neurotoxicity was reported by 5% of patients (2% grade 3 or higher).</p><p id="Par21">CC93269 is an asymmetric two arm IgG1-based human BiTE antibody that binds bivalently to BCMA and monovalently to CD3&#949; [<xref ref-type="bibr" rid="CR61">61</xref>]. The CC-93269-MM-001 trial ( <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03486067">NCT03486067</ext-link>, Phase 1, multiple countries) has enrolled 19 RRMM patients treated with median 6 prior lines of therapy [<xref ref-type="bibr" rid="CR14">14</xref>].ORR was 83.3% (&#8805;&#8201;6&#160;mg CC-93269 in Cycle 1) in evaluable patients, with 33.3% achieving sCR and 75% achieving MRD-negativity at a follow-up interval ranging from 2.1 to 4.7&#160;months. Grade 3&#8211;4 AEs were reported in 78.9% of patients, including neutropenia, anemia, infection, and thrombocytopenia, although no patients required dose modifications due to toxicity. CRS was reported in 89.5% of patients (of which 94% had grade 1&#8211;2). One death was reported due to CRS, with infection as a possible contributing factor.</p><p id="Par22">The REGN5458 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03761108">NCT03761108</ext-link>, Phase 1, United States) has enrolled 45 RRMM patients treated with median 5 prior lines of therapy in a safety trial with REGN5458, a BiTE antibody also targeting BCMA and CD3 [<xref ref-type="bibr" rid="CR17">17</xref>]. ORR was 36% across all dose levels, with 31% achieving at least CR. Most common AEs include CRS (38%, all grades 1&#8211;2), fatigue (18%), and nausea (18%), with dose-limiting toxicities including acute kidney injury and elevated liver transaminases. Serious treatment-associated AEs occurred in 22% of patients; the most common was CRS (11%).</p><p id="Par23">The TNB383B trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03933735">NCT03933735</ext-link>, Phase 1, United States) has enrolled 38 patients treated with median 7 prior lines of therapy [<xref ref-type="bibr" rid="CR16">16</xref>]. TNB-383 is a BiTE targeting BCMA and CD3, with proprietary technology optimizing high affinity for BCMA with low-activating CD3 to minimize toxicity due to cytokine secretion from strong activation of CD3. ORR was 37% in evaluable patients, with a median duration of response of 9&#160;weeks. The most common AEs were CRS (21%, all grade 1&#8211;2) and headache (13%); the most common grade 3&#8211;4 AEs were anemia (16%) and thrombocytopenia (13%).</p><p id="Par24">The PF-06863135 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03269136">NCT03269136</ext-link>, Phase 1, United States and Canada) has enrolled 18 RRMM patients treated with median 7 prior lines of therapy in a dose-escalation safety trial [<xref ref-type="bibr" rid="CR15">15</xref>]. PF-3135 is another BiTE antibody consisting of BCMA and CD3 targeting arms. ORR was 33% for evaluable patients (75% at the top two dosing tiers). Most common AEs were CRS (61%, all had grade 1&#8211;2), anemia (50%), and thrombocytopenia (39%). Grade 3&#8211;4 AEs were observed in 67% of patients; grade 4 AEs included lymphopenia (22%), thrombocytopenia (17%), and neutropenia (11%). Grade 5 AEs occurred in 17% of patients, but were not thought to be treatment-related.</p><p id="Par25">Bispecific antibodies against other antigens on malignant cells aside from BCMA have also been created. The talquetamab trial (JNJ-64407564, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03399799">NCT03399799</ext-link>, Phase 1, multiple countries) has enrolled 137 patients treated with median 6 prior lines of therapy in a dose escalation study with talquetamab, a BiTE antibody targeting GPRC5D and CD3 which can be administered intravenously or subcutaneously [<xref ref-type="bibr" rid="CR18">18</xref>]. GPRC5D is an orphan receptor with high selective expression in primary myeloma cells [<xref ref-type="bibr" rid="CR62">62</xref>]. ORR ranged from 78% (intravenous) to 67% (subcutaneous) in evaluable patients, with a median onset of response of 1&#160;month. The most frequent AEs included anemia (50%), CRS (47%, mostly grade 1&#8211;2, with &lt;&#8201;8% grade 3), and neutropenia (45%). Neurotoxicity was reported in 5% of patients (57% grade 1&#8211;2).</p><p id="Par26">The GO39775 trial (BFCR4350A, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03275103">NCT03275103</ext-link>, Phase 1, multiple countries) has enrolled 51 patients treated with median 6 prior lines of therapy in a safety trial evaluating BFCR4350A, a BiTE antibody targeting FcRH5 and CD3 [<xref ref-type="bibr" rid="CR19">19</xref>]. FcRH5 is a membrane protein expressed on B and plasma cells, with almost 100% expression on observed myeloma cells [<xref ref-type="bibr" rid="CR63">63</xref>]. ORR was 52% in evaluable patients, with 40% of these patients demonstrating durable response 6&#160;months following therapy. The most common AEs were CRS (75%, of which 97% were grade 1&#8211;2), neutropenia (12%), and thrombocytopenia (10%).</p></sec><sec id="Sec7"><title>Antibody&#8211;drug conjugates (ADCs)</title><p id="Par27">Antibody&#8211;drug conjugates consist of recombinant monoclonal antibodies covalently bound to cytotoxic chemicals (known as warheads or payload) via synthetic linkers [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Since gemtuzumab ozogamicin for relapsed acute myelogenous leukemia became the first ADC to gain approval by the United States Food and Drug Administration (FDA) in 2010, there has been a total of eight additional approvals. Currently, three generations of ADCs were developed, with enhancing stability and potency while minimizing toxicity in each subsequent generation [<xref ref-type="bibr" rid="CR64">64</xref>]. Belantamab mafodotin (GlaxoSmithKline) was the first agent approved for RRMM in August 2020 [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par28">The MEDI-2228 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03489525">NCT03489525</ext-link>, Phase 1, multiple countries) has enrolled 82 RRMM patients treated with at least 3 prior lines of therapy in a dose-escalating study testing MEDI-2228, an ADC linking an anti-BCMA antibody which is conjugated to a DNA cross-linking pyrrolobenzodiazepine dimer [<xref ref-type="bibr" rid="CR20">20</xref>]. Efficacy was seen at all dose levels, with ORR being 61% at the maximally tolerated dose. Most common AEs occurring at the maximal dose included photophobia (54%), thrombocytopenia (32%), and rash (29%), with no reports of keratopathy or visual acuity loss.</p><p id="Par29">The TAK-169 trial (TAK-169, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04017130">NCT04017130</ext-link>, Phase 1, United States) plans to enroll 114 RRMM patients in a two-part clinical trial to assess the safety and preliminary clinical activity of TAK169, a fusion protein comprised of an anti-CD38 antibody single chain variable fragment fused to a modified Shiga-like toxin-A subunit [<xref ref-type="bibr" rid="CR21">21</xref>]. The proposed agent specifically binds to CD38+ cells, undergoes forced internalization of the target cell and retrograde transport to the cytosol, and finally irreversibly inactivates target cell ribosomes causing apoptosis. This mechanism is considered novel from standard ADCs and may be considered as a distinct class of therapeutics (engineered toxin bodies) with continued clinical success. In vitro, in vivo, and ex vivo assays were performed demonstrating significant direct tumor cell kill activity independent of the patient&#8217;s innate immune status. Current enrollment is ongoing (Table <xref rid="Tab4" ref-type="table">4</xref>), and additional targets, including SLAMF7 with the same therapeutic construct, are being investigated [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par30">Other targeted antigens include CD123 (tagraxofusp, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02661022">NCT02661022</ext-link>, phase 1, United States), an antigen expressed by plasmacytoid dendritic cells which is also found in the multiple myeloma bone marrow microenvironment [<xref ref-type="bibr" rid="CR68">68</xref>]. Tagraxofusp is a CD123-directed cytotoxin fused to a truncated diphtheria toxin approved for blastic plasmacytoid dendritic-cell neoplasm [<xref ref-type="bibr" rid="CR69">69</xref>]. Nine RRMM patients were treated with median 3 lines of prior therapy received tagraxofusp with pomalidomide and dexamethasone, with 56% reporting partial response in tumor reduction and &gt;&#8201;50% decrease in peripheral blood plasmacytoid dendritic cell levels. The most common AEs were hypoalbuminemia (67%), chills (56%), and fatigue (56%); the most common grade 3&#8211;4 AEs were thrombocytopenia (44%) and neutropenia (33%), with no grade 5 events reported.</p><p id="Par31">Finally, there are also efforts to create amanitin-based ADCs which are expected to have additional action against non-proliferating myeloma cells in contrast to ADCs utilizing microtubule- or DNA-targeting toxins which are more effective in actively dividing cells. HDP-101 is a new ADC targeting BCMA linked to amanitin especially aimed at targeting myeloma cells with <italic toggle="yes">TP53</italic> deletions in chromosome 17p [<xref ref-type="bibr" rid="CR70">70</xref>]. Amanitin is active against RNA polymerase II, of which a major subunit is frequently co-deleted with <italic toggle="yes">TP53</italic> in cells with chromosome 17p deletions [<xref ref-type="bibr" rid="CR71">71</xref>]. Preclinical studies demonstrated efficacy and tolerance [<xref ref-type="bibr" rid="CR72">72</xref>]; clinical trials are forthcoming.</p></sec><sec id="Sec8"><title>Monoclonal antibodies (MoAbs)</title><p id="Par32">Since 2015, monoclonal antibodies have become a stalwart of RRMM therapy, with recent approval of daratumumab as the frontline treatment in NDMM [<xref ref-type="bibr" rid="CR73">73</xref>]. Currently, there are three FDA-approved monoclonal antibodies: daratumumab (anti-CD38), elotuzumab (anti-SLAMF7), and isatuximab (anti-CD38).</p><p id="Par33">The TAK-079 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03439280">NCT03439280</ext-link>, Phase 1, United States) has enrolled 34 RRMM patients treated with median 4 prior lines of therapy in the TAK-079 trial [<xref ref-type="bibr" rid="CR22">22</xref>]. TAK-079 is a subcutaneously administered anti-CD38 antibody that induces apoptosis via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity [<xref ref-type="bibr" rid="CR74">74</xref>]. At the recommended phase 2 dose, the authors report a preliminary efficacy of ORR 33% in evaluable subjects who received at least 6 cycles of therapy. The clinical benefit rate at the recommended phase 2 dose (minimal response or better) was 67%, with PFS not estimable given the current median follow-up of 7.5&#160;months. The most common AEs were fatigue (21%), anemia (18%), neutropenia (18%), and leukopenia (15%), with only neutropenia being the only grade 3 AE. The only drug-related significant AE was grade 3 diverticulitis, with no grade 4 AEs, AEs leading to study discontinuation, or deaths secondary to AEs.</p><p id="Par34">A related anti-CD38 therapeutic trial, TAK-573 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03215030">NCT03215030</ext-link>, Phase 1, United States) is currently in progress and has enrolled 59 patients with median 7 lines of prior therapy in a phase 1 dose-finding trial [<xref ref-type="bibr" rid="CR23">23</xref>]. TAK-573, designed for directed interferon delivery contains an anti-CD38 monoclonal antibody fused to two attenuated interferon molecules. Response has been seen at nearly all dosing levels, with most common AEs being thrombocytopenia (83%, 47% grade 3 and above) and neutropenia (54%, 49% grade 3 and above).</p><p id="Par35">SAR442085 is another anti-CD38 antibody currently beginning phase I trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04000282">NCT04000282</ext-link>, Phase 1, multiple countries) [<xref ref-type="bibr" rid="CR24">24</xref>]. The authors report that SAR442085 has a higher affinity for activating receptors on effector cells compared to daratumumab, resulting in an increased ability to engage CD16 with a higher level of NK cell activation.</p><p id="Par36">Other target antigens currently being explored include CD47 (AO-176, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03834948">NCT03834948</ext-link>, Phase 1, United States), an innate immune checkpoint found to be overexpressed on cancer cells [<xref ref-type="bibr" rid="CR75">75</xref>&#8211;<xref ref-type="bibr" rid="CR77">77</xref>]. AO-176 was found to not only promote phagocytosis of hematologic tumor cell lines but also directly target and kill tumor cells. Animal in vivo studies show complete tumor regression combined with bortezomib, including improved overall survival. Enrollment in phase 1 trial is ongoing for RRMM (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445701">NCT04445701</ext-link>).</p></sec><sec id="Sec9"><title>Small molecule inhibitors and modulators</title><p id="Par37">Small molecule inhibitors and modulators comprise the final major class of multiple myeloma therapy. Currently approved therapies include proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulators (lenalidomide, pomalidomide, thalidomide), histone deacetylase inhibitors (panobinostat), and the novel nuclear export inhibitor, selinexor, which was approved July 2019 [<xref ref-type="bibr" rid="CR78">78</xref>]. Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref> is a schematic of the major pathways of approved small molecule therapeutics described in this review, with current FDA-approved therapies for multiple myeloma highlighted in red text and investigational therapeutics in blue text. Phase 1 targeted therapy trials in this category initiated since 2019 are listed in Table <xref rid="Tab5" ref-type="table">5</xref>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Mechanism of small molecule therapeutics in multiple myeloma therapy. FDA-approved medications are shown in red text and investigational therapies discussed in review text and Table <xref rid="Tab4" ref-type="table">4</xref> are shown in blue text</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13045_2021_1109_Fig3_HTML.jpg"/></fig><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Phase 1 and early phase 1 small molecule inhibitors/modulators for RRMM, as of December 31, 2020, with study start date after January 1, 2019</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Target pathway</th><th align="left" colspan="1" rowspan="1">Product name (NCT)</th><th align="left" colspan="1" rowspan="1">Study sponsor</th><th align="left" colspan="1" rowspan="1">Estimated enrollment</th><th align="left" colspan="1" rowspan="1">Country</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Adenosine-2A receptor</td><td align="left" colspan="1" rowspan="1">Ciforadenant (CPI-444) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04280328">NCT04280328</ext-link>)</td><td align="left" colspan="1" rowspan="1">Corvus</td><td char="." align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">Arginase</td><td align="left" colspan="1" rowspan="1">INCB001158 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03837509">NCT03837509</ext-link>)</td><td align="left" colspan="1" rowspan="1">Incyte</td><td align="left" colspan="1" rowspan="1">98</td><td align="left" colspan="1" rowspan="1">United States, Germany, Spain</td></tr><tr><td align="left" colspan="1" rowspan="1">Bcl-2/Bcl-xL (apoptosis regulator)</td><td align="left" colspan="1" rowspan="1">AZD0466 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04214093">NCT04214093</ext-link>)</td><td align="left" colspan="1" rowspan="1">AstraZeneca</td><td align="left" colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">Bcl-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="S65487">S65487</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03755154">NCT03755154</ext-link>)</td><td align="left" colspan="1" rowspan="1">Institut de Recherches Internationales Servier</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">Australia, France, Spain, United Kingdom</td></tr><tr><td align="left" colspan="1" rowspan="1">BTK (Bruton&#8217;s tyrosine kinase)</td><td align="left" colspan="1" rowspan="1">Ibrutinib (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03702725">NCT03702725</ext-link>)</td><td align="left" colspan="1" rowspan="1">Alliance Foundation</td><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">Cereblon E3 ubiquitin ligase (CELMoD &#8211; protein homeostasis)</td><td align="left" colspan="1" rowspan="1">CC-92480 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03989414">NCT03989414</ext-link>)</td><td align="left" colspan="1" rowspan="1">Celgene</td><td char="." align="char" colspan="1" rowspan="1">215 (includes NDMM)</td><td align="left" colspan="1" rowspan="1">United States, Canada, Denmark, Finland, Spain, United Kingdom</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-15 receptor (cytokine signaling)</td><td align="left" colspan="1" rowspan="1">NKTR-255 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04136756">NCT04136756</ext-link>)</td><td align="left" colspan="1" rowspan="1">Nektar</td><td align="left" colspan="1" rowspan="1">87</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">IRF4 (lymphocyte transcriptional factor)</td><td align="left" colspan="1" rowspan="1">ION251 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04398485">NCT04398485</ext-link>)</td><td align="left" colspan="1" rowspan="1">Ionis</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">JAK (Janus kinase/tyrosine kinase)</td><td align="left" colspan="1" rowspan="1">Ruxolitinib (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03773107">NCT03773107</ext-link>)</td><td align="left" colspan="1" rowspan="1">Incyte</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">LMP7 (proteasome complex subunit)</td><td align="left" colspan="1" rowspan="1">M3258 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04075721">NCT04075721</ext-link>)</td><td align="left" colspan="1" rowspan="1">EMD Serono</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">United States, France</td></tr><tr><td align="left" colspan="1" rowspan="1">Mcl-1 (apoptosis control)</td><td align="left" colspan="1" rowspan="1">ABBV-467 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04178902">NCT04178902</ext-link>)</td><td align="left" colspan="1" rowspan="1">AbbVie</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">United States, Australia, France, Israel, Japan, Spain, Taiwan</td></tr><tr><td align="left" colspan="1" rowspan="1">Mcl-1</td><td align="left" colspan="1" rowspan="1">PRT1419 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04543305">NCT04543305</ext-link>)</td><td align="left" colspan="1" rowspan="1">Prelude</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">NEDD8 (ubiquitin-like protein)</td><td align="left" colspan="1" rowspan="1">Pevonedistat (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03770260">NCT03770260</ext-link>)</td><td align="left" colspan="1" rowspan="1">National Cancer Institute</td><td align="left" colspan="1" rowspan="1">66</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">p300/CBP (transcriptional coactivating proteins)</td><td align="left" colspan="1" rowspan="1">CCS1477 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04068597">NCT04068597</ext-link>)</td><td align="left" colspan="1" rowspan="1">CellCentric</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">United Kingdom</td></tr><tr><td align="left" colspan="1" rowspan="1">Proteasome inhibitor</td><td align="left" colspan="1" rowspan="1">TQB3602 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04275583">NCT04275583</ext-link>)</td><td align="left" colspan="1" rowspan="1">Chia Tai Tianqing</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">RAD51 (DNA repair protein)</td><td align="left" colspan="1" rowspan="1">CYT-0851 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03997968">NCT03997968</ext-link>)</td><td align="left" colspan="1" rowspan="1">Cyteir</td><td align="left" colspan="1" rowspan="1">165</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">S100A9 (regulation of immune response and inflammation)</td><td align="left" colspan="1" rowspan="1">Tasquinimod (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405167">NCT04405167</ext-link>)</td><td align="left" colspan="1" rowspan="1">University of Pennsylvania</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">TIGIT (T and NK cell immune receptor)</td><td align="left" colspan="1" rowspan="1">COM902 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04354246">NCT04354246</ext-link>)</td><td align="left" colspan="1" rowspan="1">Compugen</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">TIGIT</td><td align="left" colspan="1" rowspan="1">Tiragolumab (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04045028">NCT04045028</ext-link>)</td><td align="left" colspan="1" rowspan="1">Genentech</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">United States, Korea</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-TIGIT and anti-LAG</td><td align="left" colspan="1" rowspan="1">BMS-986016 and BMS-986207 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04150965">NCT04150965</ext-link>)</td><td align="left" colspan="1" rowspan="1">Multiple Myeloma Research Consortium</td><td align="left" colspan="1" rowspan="1">104</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)</td><td align="left" colspan="1" rowspan="1">Eftozanermin alfa (ABBV-621) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04570631">NCT04570631</ext-link>)</td><td align="left" colspan="1" rowspan="1">AbbVie</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">United States, France, German, Italy, Japan, Spain</td></tr><tr><td align="left" colspan="1" rowspan="1">Specific targeted therapy based on mutations uncovered with genomic studies</td><td align="left" colspan="1" rowspan="1">MyDRUG (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03732703">NCT03732703</ext-link>)</td><td align="left" colspan="1" rowspan="1">Multiple Myeloma Research Consortium</td><td align="left" colspan="1" rowspan="1">228</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">Specific targeted therapy based on mutations uncovered with genomic studies</td><td align="left" colspan="1" rowspan="1">SMMART PRIME (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03878524">NCT03878524</ext-link>)</td><td align="left" colspan="1" rowspan="1">Oregon Health and Science University</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">United States</td></tr></tbody></table></table-wrap></p><sec id="Sec10"><title>BCL-2/MCL-1 inhibitors</title><p id="Par38">Venetoclax is an oral inhibitor of the BCL-2 protein which regulates the intrinsic mitochondrial apoptotic pathway as an anti-apoptotic. Venetoclax binds to BCL-2 and terminates the suppression of proapopotic proteins BAX and BAK, promoting cell death of the target cell (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Venetoclax is approved for chronic lymphocytic leukemia and acute myeloid leukemia and was further explored in RRMM, initially as single agent and later in combination with Velcade [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Due to BCL-2 and cyclin D1 overexpression in <italic toggle="yes">t</italic>(11;14) multiple myeloma patients (up to 20%), venetoclax is increasingly being investigated as a therapeutic targeted agent in this patient population. Venetoclax trials in RRMM was halted due to findings from the Bellini trial with increased mortality seen in the venetoclax group, mostly due to an increased rate of infection [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par39">Venetoclax was combined with Daratumumab in M15-654 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03314181">NCT03314181</ext-link>, Phase 1/2, multiple countries) which enrolled 48 RRMM patients in two groups [<xref ref-type="bibr" rid="CR82">82</xref>]. In Part 1, patients with <italic toggle="yes">t</italic>(11;14) who received &#8805;&#8201;1 prior line of therapy (PI and an IMIDs) were treated with VenDd. In Part 2, patients irrespective of <italic toggle="yes">t</italic>(11;14) status, non-refractory to PIs and failed 1&#8211;3 prior lines of therapy were treated with VenDVd.&#160;Frequent Grade&#8201;&#8805;&#8201;3 AEs in patients on VenDd were neutropenia (17%), hypertension (12%), fatigue and hyperglycemia (8% each), and in patients on VenDVd were insomnia (21%), diarrhea and thrombocytopenia (8% each). Eighteen patients had a serious AE (11 VenDd, 7 VenDVd), with pyrexia (n&#8201;=&#8201;3) being most common. Median follow-up (VenDd/VenDVd) was 10 and 9&#160;months. Overall response rate in VenDd/VenDVd was 96%/92% and 96%/79% had &#8805;&#8201;very good partial response rate. Median progression free survival and duration of response were not reached.</p><p id="Par40">Novel Bcl-2 inhibitor AT-101 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02697344">NCT02697344</ext-link>, Phase 1, United States) enrolled 10 RRMM patients treated with median 2 prior lines of therapy in a safety and preliminary efficacy trial [<xref ref-type="bibr" rid="CR27">27</xref>]. AT-101 is a pan BCL-2 inhibitor and the trial combined it with lenalidomide. ORR was 44% in evaluable patients, and median PFS was 8.1&#160;months. Dose-limiting toxicities included grade 4 febrile neutropenia and thrombocytopenia. Most common grade 3&#8211;4 AEs included neutropenia, leukopenia, and thrombocytopenia. No patients experienced TLS.</p><p id="Par41">Finally, MCL-1 is another antiapoptotic member of the BCL-2 family of proteins. Similar to BCL-2, MCL-1 binds to pro-apoptotic proteins BAK and BAX, and MCL-1 inhibitors remove that regulation and induce apoptosis via the intrinsic mitochondrial pathway [<xref ref-type="bibr" rid="CR83">83</xref>]. Several MCL-1 inhibitor trials are underway, with promising preclinical data demonstrating in vitro tumor cell death and in vivo tumor growth inhibition [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Thus far, phase 1 clinical trials are ongoing.</p></sec><sec id="Sec11"><title>Histone deacetylase (HDAC) inhibitors</title><p id="Par42">The only HDAC inhibitor approved for multiple myeloma is panobinostat, approved in 2015 following the PANORAMA1 trial [<xref ref-type="bibr" rid="CR86">86</xref>]. Panobinostat combined with bortezomib and dexamethasone achieved a median PFS of 12.0&#160;months compared to 5.5&#160;months in the placebo group. However, grade 3&#8211;4 AEs occurred in 96% of patients in the panobinostat group, compared to 82% in the placebo group. Panobinostat was ultimately approved with black box warnings for severe diarrhea (68% in the panobinostat cohort and 25% being grade 3&#8211;4, with 42% in the placebo group and 8% being grade 3&#8211;4) and EKG changes (prolonged QTc).</p><p id="Par43">Since panobinostat, research into other promising agents in the family of HDAC inhibitors has continued (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). There are 18 defined HDACs which play crucial roles in histone deacetylation, an important epigenetic modification that activates DNA transcription and is implicated in neoplastic growth. HDAC inhibitors reduce the activity of aberrant myeloma cells by inducing histone hyperacetylation, leading to cell cycle arrest and apoptosis [<xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par44">The alteminostat trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03150316">NCT03150316</ext-link>, Phase 1, South Korea) has enrolled 10 RRMM patients treated with median of 2.5 prior lines of therapy in a trial designed to assess alteminostat in combination with lenalidomide and dexamethasone [<xref ref-type="bibr" rid="CR28">28</xref>]. Alteminostat is a novel pan-HDAC inhibitor with significant in vitro growth inhibition of multiple myeloma cell lines, especially in reducing the secretion of interleukin 6, which is associated with the proliferation of myeloma cells [<xref ref-type="bibr" rid="CR88">88</xref>]. ORR was 70% in evaluable patients with 10% sCR, and median PFS was 7.7&#160;months. Most common AEs included thrombocytopenia (80%), neutropenia (60%), and anemia (50%). No serious AEs, including cardiac disorders, were reported. The most common grade 3&#8211;4 AEs were neutropenia (70%), thrombocytopenia (60%), and anemia (60%).</p><p id="Par45">The chidamide trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04025450">NCT04025450</ext-link>, Phase 1, China) has enrolled 12 NDMM patients with high-risk characteristics in a clinical trial designed to assess chidamide in combination with bortezomib, lenalidomide, and dexamethasone [<xref ref-type="bibr" rid="CR29">29</xref>]. Chidamide is a selective HDAC inhibitor targeting HDAC 1, 2, 3, and 10 which is currently approved in China for the treatment of peripheral T cell lymphomas [<xref ref-type="bibr" rid="CR89">89</xref>]. Preclinical studies have indicated increased apoptosis and cell cycle arrest in treated myeloma cells [<xref ref-type="bibr" rid="CR90">90</xref>]. In the clinical trial, ORR was 100% for evaluable patients, and 77% of patients obtained VGPR after one cycle. AEs included leukopenia, thrombocytopenia, and transaminase elevation. Grade 3&#8211;4 AEs were reported for thrombocytopenia and transaminase elevation. Two patients discontinued the study due to acute cardiac and acute renal failure.</p><p id="Par46">In order to mitigate the toxicity associated with pan-HDAC inhibitors, preclinical studies have investigated selective HDAC6/8 inhibition (JBI-802, CVL608, CS3003) with demonstrable in vitro and in vivo myeloma growth inhibition [<xref ref-type="bibr" rid="CR91">91</xref>&#8211;<xref ref-type="bibr" rid="CR93">93</xref>]. These novel agents herald the arrival of more tailored approaches to HDAC inhibition in the future.</p></sec><sec id="Sec12"><title>Cereblon E3 ligase modulating drugs (CELMoD)</title><p id="Par47">Lenalidomide, pomalidomide, and thalidomide are immunomodulators of cereblon E3 ligase, an essential enzyme in the cellular protein homeostasis machinery [<xref ref-type="bibr" rid="CR94">94</xref>]. Proteins recruited cereblon E3 ligase are tagged with chains of ubiquitin and subsequently digested by the proteasome. CELMoDs bind to the surface of cereblon and recruit transcription factors such as Ikaros (IKZF1) and Aiolos (IKZF3) which are overexpressed in myeloma cells. These transcription factors are then ubiquitinated and targeted for subsequent destruction, leading to eventual host cell death (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). There are currently several CELMoDs under clinical investigation [<xref ref-type="bibr" rid="CR95">95</xref>].</p><p id="Par48">The CC-220-MM-001 trial (iberdomide, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02773030">NCT02773030</ext-link>, Phase 1/2, multiple countries) is a dose-escalation trial combining iberdomide with different treatment combinations. Thus far, it has demonstrated a favorable safety profile when combined with dexamethasone [<xref ref-type="bibr" rid="CR96">96</xref>]. 19 patients received iberdomide in combination with daratumumab and dexamethasone (IberDd, median 4 prior lines of therapy) and 21 patients received iberdomide in combination with bortezomib and dexamethasone (IberVd, median 6 prior lines of therapy) [<xref ref-type="bibr" rid="CR30">30</xref>]. ORR was 35% with IberDd and 50% with IberVd in evaluable patients. Median time to response was 4.1 and 4.9&#160;weeks in both cohorts, respectively. Grade 3&#8211;4 AEs were reported in 78% with IberDd, most common being neutropenia (50%) and anemia (22%); 65% of patients with IberVd, most common being neutropenia (20%) and thrombocytopenia (20%).</p><p id="Par49">The CC-92480 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03374085">NCT03374085</ext-link>, Phase 1, multiple countries) enrolled RRMM patients in a first-in-human study to evaluate the biological and clinical effects of CC-92480 and dexamethasone in heavily pretreated multiple myeloma patients [<xref ref-type="bibr" rid="CR31">31</xref>]. The authors reported that Ikaros and Aiolos dose-associated degradation with concurrent T cell proliferation. CC-92480 led to rapid and sustained decreases in serum free light chains, although gaps in drug administration led to rapid rebound of these markers. Other CELMoDs (KPG-818, BTX-PHM) are currently under investigation, with favorable preclinical data [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>].</p></sec><sec id="Sec13"><title>MEK and BRAF inhibitors</title><p id="Par50">Given the prevalence of MAPK pathway mutations in over 50% of newly-diagnosed myeloma patients [<xref ref-type="bibr" rid="CR99">99</xref>], a trial investigating cobimetinib (cobimetinib, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03312530">NCT03312530</ext-link>, Phase 1/2, multiple countries) enrolled 49 RRMM patients with median 4 prior lines of therapy in studies investigating the efficacy of MEK inhibition alone and combined with venetoclax (BCL-2 inhibition) and atezolizumab (PD-L1 inhibition) [<xref ref-type="bibr" rid="CR32">32</xref>]. ORR was 0% for cobimetinib alone (C), 27% for cobimetinib combined with venetoclax (C&#8201;+&#8201;V), and 29% for cobimetinib combined with venetoclax and atezolizumab (C&#8201;+&#8201;V&#8201;+&#8201;A). Median duration of response was 11.5&#160;months and 5.1&#160;months for the C&#8201;+&#8201;V and C&#8201;+&#8201;V&#8201;+&#8201;A arms, respectively. The most common adverse effects (C/C&#8201;+&#8201;V/C&#8201;+&#8201;V&#8201;+&#8201;A) were diarrhea (33%/82%/91%), nausea (17%/50%/67%), and anemia (17%/46%/57%). Two cases of tumor lysis syndrome were reported, and treatment discontinuation were similar across the three arms at 14&#8211;18%.</p><p id="Par51">Another trial using encorafenib and binimetinib (encorafenib and binimetinib, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02834364">NCT02834364</ext-link>, Phase 2, Germany) enrolled 12 patients with median 5 prior lines of therapy in a study investigating BRAF and MEK inhibition in RRMM patients with BRAF V600E mutation; activating mutations of BRAF are found in up to 10% of RRMM patients[<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. ORR was 82% with 27% of evaluable patients reaching CR. PFS assessment is still in progress, but duration of response exceeding 1&#160;year was observed. Most common grade 3&#8211;4 AEs included anemia (25%), hypertension (25%), and thrombocytopenia (17%).</p></sec></sec><sec id="Sec14"><title>Other investigational therapies</title><p id="Par52">Other current investigational therapies include oncolytic targeted vaccines [<xref ref-type="bibr" rid="CR101">101</xref>&#8211;<xref ref-type="bibr" rid="CR104">104</xref>], enhancements to existing T cell-directed therapies [<xref ref-type="bibr" rid="CR105">105</xref>], and other types of adoptive cell therapy aside from CAR-T cells [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. Trials studying chemotherapy agents such as bendamustine and arsenic have decreased in recent years in favor of targeted therapeutics [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>], although there are ongoing efforts to examine the efficacy of these agents in specialized populations [<xref ref-type="bibr" rid="CR110">110</xref>&#8211;<xref ref-type="bibr" rid="CR112">112</xref>].</p><p id="Par53">Melphalan flufenamide (Melflufen), a peptidase enhanced cytotoxic derivative of melphalan with targeted delivery of melphalan via membrane bound aminopeptidase N (APN or AD13) [<xref ref-type="bibr" rid="CR113">113</xref>], has demonstrated favorable in vitro and ex vivo effects on high risk multiple myeloma cell lines with del17p and TP53 mutations [<xref ref-type="bibr" rid="CR114">114</xref>]. Melphalan flufenamide combined with dexamethasone was approved by the&#160;FDA in February&#160;2021 based on HORIZON trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02963493">NCT02963493</ext-link>) in RRMM patients who failed at least four prior lines of therapy [<xref ref-type="bibr" rid="CR115">115</xref>].</p></sec><sec id="Sec15"><title>Conclusion</title><p id="Par54">Immunotherapy has taken central stage thanks to relentless technological advancement and drug development. CAR-T/NK, BITEs, and ADCs, followed by novel small molecule targeted inhibitors/modulators, have shifted the multiple myeloma therapeutic paradigm. The ongoing trials with these novel agents offer patients various avenues of potential promising treatment options. Nevertheless, we are still facing many challenges ahead in RRMM management: how to achieve sustained deep remission, how to sequence and combine agents of different mechanisms of action, how to better manage and even prevent adverse effects, and how to improve and optimize convenience of drug administrations to patients.</p><p id="Par55">Furthermore, drug resistance and immune escape are particularly complicated and challenging in the novel immunotherapies in RRMM, thus calling for more thought-provoking ideas to study mechanistic biology in basic and translational research [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>], better designed clinical trials to enrich patient populations stratified by meaningful biomarkers, and consolidated efforts to conduct high quality trials to generate&#160;practice changing data that&#160;can benefit our myeloma patients.
</p><p id="Par56">The financial costs associated with these novel therapies is another important issue for consideration: for instance,&#160;whether society, health system and patients can afford the expense of treatments such as CAR-T. However, patients can benefit from CAR-T as a promising therapy and enjoy a treatment break&#160;from chronic therapy [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>].&#160;Treatment de-escalation in subset of the patients who achieved sustained deep response can not only&#160;spare patients from unnecessary long term drug toxicity, but also significantly reduce costs.</p><p id="Par57">In summary, the advent of the novel myeloma therapeutic landscape will continue to evolve, paving the way to a new era of highly individualized treatment regimens and sophisticated disease burden assessment, moving the needle ever closer to an eventual cure.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Figures&#160;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig3" ref-type="fig">3</xref> were created with Biorender.com.</p></ack><notes notes-type="author-contribution"><title>Authors' contributions</title><p>CTS and JCY both drafted and edited the work. Both authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>CTS is supported by a National Institutes of Health T32 Grant (T32-CA-236621).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar4"><title>Ethics approval and consent to participate</title><p id="Par58">Not applicable.</p></notes><notes id="FPar1"><title>Consent for publication</title><p id="Par59">Not applicable.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par60">CTS does not have any competing interests to declare. JCY declares research funding from Janssen, GSK, Nektar, Celgene, Takeda, Karyopharm, Sanofi, Multiple Myeloma Research Foundation, CARsgen.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikhael</surname><given-names>J</given-names></name><name name-style="western"><surname>Ismaila</surname><given-names>N</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>MC</given-names></name><name name-style="western"><surname>Costello</surname><given-names>C</given-names></name><name name-style="western"><surname>Dhodapkar</surname><given-names>MV</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>M</given-names></name><name name-style="western"><surname>Lipe</surname><given-names>B</given-names></name><name name-style="western"><surname>Little</surname><given-names>RF</given-names></name><name name-style="western"><surname>Nikonova</surname><given-names>A</given-names></name><etal/></person-group><article-title>Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><issue>14</issue><fpage>1228</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.02096</pub-id><pub-id pub-id-type="pmid">30932732</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Beurden-Tan</surname><given-names>CHY</given-names></name><name name-style="western"><surname>Franken</surname><given-names>MG</given-names></name><name name-style="western"><surname>Blommestein</surname><given-names>HM</given-names></name><name name-style="western"><surname>Uyl-de Groot</surname><given-names>CA</given-names></name><name name-style="western"><surname>Sonneveld</surname><given-names>P</given-names></name></person-group><article-title>Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>12</issue><fpage>1312</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.71.1663</pub-id><pub-id pub-id-type="pmid">28240968</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Heng</surname><given-names>HH</given-names></name></person-group><article-title>Somatic genomic mosaicism in multiple myeloma</article-title><source>Front Genet</source><year>2020</year><volume>11</volume><fpage>388</fpage><pub-id pub-id-type="doi">10.3389/fgene.2020.00388</pub-id><pub-id pub-id-type="pmid">32391059</pub-id><pub-id pub-id-type="pmcid">PMC7189895</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heng</surname><given-names>J</given-names></name><name name-style="western"><surname>Heng</surname><given-names>HH</given-names></name></person-group><article-title>Genome chaos: creating new genomic information essential for cancer macroevolution</article-title><source>Semin Cancer Biol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.11.003</pub-id><pub-id pub-id-type="pmid">33189848</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonial</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HC</given-names></name><name name-style="western"><surname>Badros</surname><given-names>A</given-names></name><name name-style="western"><surname>Trudel</surname><given-names>S</given-names></name><name name-style="western"><surname>Nooka</surname><given-names>AK</given-names></name><name name-style="western"><surname>Chari</surname><given-names>A</given-names></name><name name-style="western"><surname>Abdallah</surname><given-names>AO</given-names></name><name name-style="western"><surname>Callander</surname><given-names>N</given-names></name><name name-style="western"><surname>Lendvai</surname><given-names>N</given-names></name><name name-style="western"><surname>Sborov</surname><given-names>D</given-names></name><etal/></person-group><article-title>Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>207</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30788-0</pub-id><pub-id pub-id-type="pmid">31859245</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munshi</surname><given-names>NC</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>LD</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Madduri</surname><given-names>D</given-names></name><name name-style="western"><surname>Berdeja</surname><given-names>J</given-names></name><name name-style="western"><surname>Lonial</surname><given-names>S</given-names></name><name name-style="western"><surname>Raje</surname><given-names>N</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>D</given-names></name><name name-style="western"><surname>Oriol</surname><given-names>A</given-names></name><etal/></person-group><article-title>Idecabtagene vicleucel in relapsed and refractory multiple myeloma</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>8</issue><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2024850</pub-id><pub-id pub-id-type="pmid">33626253</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madduri</surname><given-names>D</given-names></name><name name-style="western"><surname>Berdeja</surname><given-names>JG</given-names></name><name name-style="western"><surname>Usmani</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Jakubowiak</surname><given-names>A</given-names></name><name name-style="western"><surname>Agha</surname><given-names>M</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>AK</given-names></name><name name-style="western"><surname>Hari</surname><given-names>P</given-names></name><name name-style="western"><surname>Htut</surname><given-names>M</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>E</given-names></name><etal/></person-group><article-title>CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>22</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-136307</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsina</surname><given-names>M</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Raje</surname><given-names>NS</given-names></name><name name-style="western"><surname>Jagannath</surname><given-names>S</given-names></name><name name-style="western"><surname>Madduri</surname><given-names>D</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>DS</given-names></name><name name-style="western"><surname>Munshi</surname><given-names>NC</given-names></name><name name-style="western"><surname>Rosenblatt</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>25</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-140410</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishihori</surname><given-names>T</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Blouch</surname><given-names>K</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>S</given-names></name><name name-style="western"><surname>Butler</surname><given-names>E</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>DeYoung</surname><given-names>MP</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Open-label pilot study of genetically engineered NY-ESO-1 specific T cells (GSK3377794) alone or in combination with pembrolizumab in relapsed and refractory multiple myeloma</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>3134</fpage><lpage>3134</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-128059</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>B</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>A</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>25</fpage><lpage>26</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Mei</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ai</surname><given-names>L</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name><etal/></person-group><article-title>A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>930</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-130340</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mailankody</surname><given-names>S</given-names></name><name name-style="western"><surname>Matous</surname><given-names>JV</given-names></name><name name-style="western"><surname>Liedtke</surname><given-names>M</given-names></name><name name-style="western"><surname>Sidana</surname><given-names>S</given-names></name><name name-style="western"><surname>Malik</surname><given-names>S</given-names></name><name name-style="western"><surname>Nath</surname><given-names>R</given-names></name><name name-style="western"><surname>Oluwole</surname><given-names>OO</given-names></name><name name-style="western"><surname>Karski</surname><given-names>EE</given-names></name><name name-style="western"><surname>Lovelace</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><etal/></person-group><article-title>Universal: an allogeneic first-in-human study of the anti-Bcma ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>24</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-140641</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garfall</surname><given-names>AL</given-names></name><name name-style="western"><surname>Usmani</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Mateos</surname><given-names>M-V</given-names></name><name name-style="western"><surname>Nahi</surname><given-names>H</given-names></name><name name-style="western"><surname>van de Donk</surname><given-names>NWCJ</given-names></name><name name-style="western"><surname>San-Miguel</surname><given-names>JF</given-names></name><name name-style="western"><surname>Oriol Rocafiguera</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosinol</surname><given-names>L</given-names></name><name name-style="western"><surname>Chari</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhutani</surname><given-names>M</given-names></name><etal/></person-group><article-title>Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM)</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>27</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-138831</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Wong</surname><given-names>SW</given-names></name><name name-style="western"><surname>Berm&#250;dez</surname><given-names>A</given-names></name><name name-style="western"><surname>de la Rubia</surname><given-names>J</given-names></name><name name-style="western"><surname>Mateos</surname><given-names>M-V</given-names></name><name name-style="western"><surname>Ocio</surname><given-names>EM</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Otero</surname><given-names>P</given-names></name><name name-style="western"><surname>San-Miguel</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Sarmiento</surname><given-names>R</given-names></name><etal/></person-group><article-title>First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>143</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-122895</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lesokhin</surname><given-names>AM</given-names></name><name name-style="western"><surname>Levy</surname><given-names>MY</given-names></name><name name-style="western"><surname>Dalovisio</surname><given-names>AP</given-names></name><name name-style="western"><surname>Bahlis</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Solh</surname><given-names>M</given-names></name><name name-style="western"><surname>Sebag</surname><given-names>M</given-names></name><name name-style="western"><surname>Jakubowiak</surname><given-names>A</given-names></name><name name-style="western"><surname>Jethava</surname><given-names>YS</given-names></name><name name-style="western"><surname>Costello</surname><given-names>CL</given-names></name><name name-style="western"><surname>Chu</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>8</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-133355</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>C</given-names></name><name name-style="western"><surname>D'Souza</surname><given-names>A</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Voorhees</surname><given-names>PM</given-names></name><name name-style="western"><surname>Buelow</surname><given-names>B</given-names></name><name name-style="western"><surname>Vij</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>SK</given-names></name></person-group><article-title>Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in Relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>43</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-139893</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madduri</surname><given-names>D</given-names></name><name name-style="western"><surname>Rosko</surname><given-names>A</given-names></name><name name-style="western"><surname>Brayer</surname><given-names>J</given-names></name><name name-style="western"><surname>Zonder</surname><given-names>J</given-names></name><name name-style="western"><surname>Bensinger</surname><given-names>WI</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Adriaens</surname><given-names>L</given-names></name><name name-style="western"><surname>Chokshi</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM)</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>41</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-139192</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chari</surname><given-names>A</given-names></name><name name-style="western"><surname>Berdeja</surname><given-names>JG</given-names></name><name name-style="western"><surname>Oriol</surname><given-names>A</given-names></name><name name-style="western"><surname>van de Donk</surname><given-names>NWCJ</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>P</given-names></name><name name-style="western"><surname>Askari</surname><given-names>E</given-names></name><name name-style="western"><surname>Mateos</surname><given-names>M-V</given-names></name><name name-style="western"><surname>Minnema</surname><given-names>MC</given-names></name><name name-style="western"><surname>Verona</surname><given-names>R</given-names></name><name name-style="western"><surname>Girgis</surname><given-names>S</given-names></name><etal/></person-group><article-title>A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM)</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>40</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-133873</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>A</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>R</given-names></name><name name-style="western"><surname>Forsberg</surname><given-names>PA</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name><name name-style="western"><surname>Berdeja</surname><given-names>JG</given-names></name><name name-style="western"><surname>Laubach</surname><given-names>JP</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Choeurng</surname><given-names>V</given-names></name><etal/></person-group><article-title>Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>42</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-136985</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>SK</given-names></name><name name-style="western"><surname>Migkou</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhutani</surname><given-names>M</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name><name name-style="western"><surname>Ailawadhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Kalff</surname><given-names>A</given-names></name><name name-style="western"><surname>Walcott</surname><given-names>F</given-names></name><name name-style="western"><surname>Pore</surname><given-names>N</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>26</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-136375</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>SK</given-names></name><name name-style="western"><surname>Cornell</surname><given-names>RF</given-names></name><name name-style="western"><surname>Landgren</surname><given-names>O</given-names></name><name name-style="western"><surname>Ailawadhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name><name name-style="western"><surname>Willert</surname><given-names>EK</given-names></name><name name-style="western"><surname>Waltzman</surname><given-names>R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lublinsky</surname><given-names>AR</given-names></name><etal/></person-group><article-title>A phase 1 first-in-human study of the anti-CD38 dimeric fusion protein TAK-169 for the treatment of patients (pts) with relapsed or refractory multiple myeloma (RRMM) who are proteasome inhibitor (PI)- and immunomodulatory drug (IMiD)-refractory, including Pts relapsed/refractory (R/R) or na&#239;ve to daratumumab (dara)</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>1867</fpage><lpage>1867</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-125629</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>AY</given-names></name><name name-style="western"><surname>Patel</surname><given-names>KK</given-names></name><name name-style="western"><surname>Hari</surname><given-names>P</given-names></name><name name-style="western"><surname>Jagannath</surname><given-names>S</given-names></name><name name-style="western"><surname>Niesvizky</surname><given-names>R</given-names></name><name name-style="western"><surname>Silbermann</surname><given-names>RW</given-names></name><name name-style="western"><surname>Berg</surname><given-names>DT</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Allikmets</surname><given-names>K</given-names></name><name name-style="western"><surname>Stockerl-Goldstein</surname><given-names>K</given-names></name></person-group><article-title>A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>15_suppl</issue><fpage>8539</fpage><lpage>8539</lpage><pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.8539</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogl</surname><given-names>DT</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Holstein</surname><given-names>SA</given-names></name><name name-style="western"><surname>Nadeem</surname><given-names>O</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>E</given-names></name><name name-style="western"><surname>Suryanarayan</surname><given-names>K</given-names></name><name name-style="western"><surname>Collins</surname><given-names>S</given-names></name><name name-style="western"><surname>Parot</surname><given-names>X</given-names></name><name name-style="western"><surname>Chaudhry</surname><given-names>M</given-names></name></person-group><article-title>TAK-573, an anti-CD38/attenuated Ifn&#945; fusion protein, has clinical activity and modulates the Ifn&#945; receptor (IFNAR) pathway in patients with relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>37</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-141219</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virone-Oddos</surname><given-names>A</given-names></name><name name-style="western"><surname>Kassem</surname><given-names>S</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>B</given-names></name><name name-style="western"><surname>Tang</surname><given-names>A</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>A</given-names></name><name name-style="western"><surname>El-Murr</surname><given-names>N</given-names></name><name name-style="western"><surname>Carrie-Constantin</surname><given-names>N</given-names></name><name name-style="western"><surname>Nicolazzi</surname><given-names>C</given-names></name><name name-style="western"><surname>Arnould</surname><given-names>I</given-names></name><name name-style="western"><surname>Avet-Loiseau</surname><given-names>H</given-names></name><etal/></person-group><article-title>Abstract 2266: SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>2266</fpage><lpage>2266</lpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahlis</surname><given-names>N</given-names></name><name name-style="western"><surname>Baz</surname><given-names>R</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>S</given-names></name><name name-style="western"><surname>Quach</surname><given-names>H</given-names></name><name name-style="western"><surname>Ho</surname><given-names>S-J</given-names></name><name name-style="western"><surname>Vangsted</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>S</given-names></name><name name-style="western"><surname>Salem</surname><given-names>AH</given-names></name><name name-style="western"><surname>Ross</surname><given-names>JA</given-names></name><etal/></person-group><article-title>First analysis from a phase 1/2 study of venetoclax in combination with daratumumab and dexamethasone, +/- Bortezomib, in patients with relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>925</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-124407</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gasparetto</surname><given-names>C</given-names></name><name name-style="western"><surname>Schjesvold</surname><given-names>FH</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Touzeau</surname><given-names>C</given-names></name><name name-style="western"><surname>Facon</surname><given-names>T</given-names></name><name name-style="western"><surname>Boise</surname><given-names>LH</given-names></name><name name-style="western"><surname>Alzate</surname><given-names>S</given-names></name><name name-style="western"><surname>Macartney</surname><given-names>T</given-names></name><name name-style="western"><surname>Pesko</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase I/II study evaluating the safety and efficacy of venetoclax in combination with dexamethasone as targeted therapy for patients with t(11;14) relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement 1</issue><fpage>926</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-125871</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ailawadhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Alegria</surname><given-names>VR</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name><name name-style="western"><surname>Laplant</surname><given-names>B</given-names></name><name name-style="western"><surname>Manna</surname><given-names>A</given-names></name><name name-style="western"><surname>Parrondo</surname><given-names>R</given-names></name><name name-style="western"><surname>Roy</surname><given-names>V</given-names></name><name name-style="western"><surname>Sher</surname><given-names>T</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>B</given-names></name><name name-style="western"><surname>Lanier</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase I study of a novel Bcl-2 inhibitor, at-101 in combination with lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM)</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>3137</fpage><lpage>3137</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-128610</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>CK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>DH</given-names></name><name name-style="western"><surname>Park</surname><given-names>S-S</given-names></name><name name-style="western"><surname>Han</surname><given-names>S</given-names></name></person-group><article-title>A phase 1, open-label, multi-center study of alteminostat (CKD-581) in combination with lenalidomide and dexamethasone in patients with previously treated multiple myeloma (MM)</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>1847</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-127643</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Cheng Cheng</surname><given-names>F</given-names></name></person-group><article-title>Initial safety and efficacy of dose-escalating HDACs inhibitor chidamide with VRD (Chi-VRD) treatment for newly-diagnosed high-risk transplant eligible multiple myeloma patients</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>1855</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-129434</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Donk</surname><given-names>NWCJ</given-names></name><name name-style="western"><surname>Popat</surname><given-names>R</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Minnema</surname><given-names>MC</given-names></name><name name-style="western"><surname>Jagannath</surname><given-names>S</given-names></name><name name-style="western"><surname>Oriol</surname><given-names>A</given-names></name><name name-style="western"><surname>Zonder</surname><given-names>J</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>PG</given-names></name><name name-style="western"><surname>Rodriguez-Otero</surname><given-names>P</given-names></name><name name-style="western"><surname>Badros</surname><given-names>AZ</given-names></name><etal/></person-group><article-title>First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed/refractory multiple myeloma (RRMM)</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>16</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-137743</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>L</given-names></name><name name-style="western"><surname>Lamba</surname><given-names>M</given-names></name><name name-style="western"><surname>Jim&#233;nez Nu&#241;ez</surname><given-names>MD</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>D</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>PG</given-names></name><name name-style="western"><surname>Bahlis</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Vangsted</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ramasamy</surname><given-names>K</given-names></name><name name-style="western"><surname>Trudel</surname><given-names>S</given-names></name><name name-style="western"><surname>Mart&#237;nez-Lopez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dose- and schedule-dependent immunomodulatory effects of the novel celmod agent CC-92480 in patients with relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>47</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-137161</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schjesvold</surname><given-names>F</given-names></name><name name-style="western"><surname>Ribrag</surname><given-names>V</given-names></name><name name-style="western"><surname>Rodriguez-Otero</surname><given-names>P</given-names></name><name name-style="western"><surname>Robak</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>M</given-names></name><name name-style="western"><surname>Hajek</surname><given-names>R</given-names></name><name name-style="western"><surname>Amor</surname><given-names>AA</given-names></name><name name-style="western"><surname>Martinez-L&#243;pez</surname><given-names>J</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>M</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Safety and preliminary efficacy results from a phase Ib/II study of cobimetinib as a single agent and in combination with venetoclax with or without atezolizumab in patients with relapsed/refractory multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>45</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-135845</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raab</surname><given-names>MS</given-names></name><name name-style="western"><surname>Giesen</surname><given-names>N</given-names></name><name name-style="western"><surname>Scheid</surname><given-names>C</given-names></name><name name-style="western"><surname>Besemer</surname><given-names>B</given-names></name><name name-style="western"><surname>Miah</surname><given-names>K</given-names></name><name name-style="western"><surname>Benner</surname><given-names>A</given-names></name><name name-style="western"><surname>Metzler</surname><given-names>I</given-names></name><name name-style="western"><surname>Khandanpour</surname><given-names>C</given-names></name><name name-style="western"><surname>Seidel-Glaetzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Trautmann-Grill</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety and preliminary efficacy results from a phase II study evaluating combined BRAF and MEK inhibition in relapsed/refractory multiple myeloma (rrMM) patients with activating BRAF V600E mutations: the GMMG-Birma trial</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>44</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-142600</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ocio</surname><given-names>EM</given-names></name><name name-style="western"><surname>Efebera</surname><given-names>YA</given-names></name><name name-style="western"><surname>H&#225;jek</surname><given-names>R</given-names></name><name name-style="western"><surname>Granell</surname><given-names>M</given-names></name><name name-style="western"><surname>Maisnar</surname><given-names>V</given-names></name><name name-style="western"><surname>Straub</surname><given-names>J</given-names></name><name name-style="western"><surname>Eveillard</surname><given-names>J-R</given-names></name><name name-style="western"><surname>Karlin</surname><given-names>L</given-names></name><name name-style="western"><surname>Ribrag</surname><given-names>V</given-names></name><name name-style="western"><surname>Mateos</surname><given-names>M-V</given-names></name><etal/></person-group><article-title>ANCHOR (OP-104): melflufen plus dexamethasone (dex) and daratumumab (dara) or bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) refractory to an IMiD and/or a proteasome inhibitor (PI)&#8212;updated efficacy and safety</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>9</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-135991</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateos</surname><given-names>M-V</given-names></name><name name-style="western"><surname>Oriol</surname><given-names>A</given-names></name><name name-style="western"><surname>Larocca</surname><given-names>A</given-names></name><name name-style="western"><surname>Blade</surname><given-names>J</given-names></name><name name-style="western"><surname>Cavo</surname><given-names>M</given-names></name><name name-style="western"><surname>Otero</surname><given-names>PR</given-names></name><name name-style="western"><surname>Leleu</surname><given-names>X</given-names></name><name name-style="western"><surname>Hiemenz</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hassoun</surname><given-names>H</given-names></name><name name-style="western"><surname>Touzeau</surname><given-names>C</given-names></name><etal/></person-group><article-title>HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex)</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>15_suppl</issue><fpage>e20570</fpage><lpage>e20570</lpage><pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.e20570</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gagelmann</surname><given-names>N</given-names></name><name name-style="western"><surname>Riecken</surname><given-names>K</given-names></name><name name-style="western"><surname>Wolschke</surname><given-names>C</given-names></name><name name-style="western"><surname>Berger</surname><given-names>C</given-names></name><name name-style="western"><surname>Ayuk</surname><given-names>FA</given-names></name><name name-style="western"><surname>Fehse</surname><given-names>B</given-names></name><name name-style="western"><surname>Kr&#246;ger</surname><given-names>N</given-names></name></person-group><article-title>Development of CAR-T cell therapies for multiple myeloma</article-title><source>Leukemia</source><year>2020</year><volume>34</volume><issue>9</issue><fpage>2317</fpage><lpage>2332</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-0930-x</pub-id><pub-id pub-id-type="pmid">32572190</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name></person-group><article-title>Engineering better chimeric antigen receptor T cells</article-title><source>Exp Hematol Oncol</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s40164-020-00190-2</pub-id><pub-id pub-id-type="pmid">33292660</pub-id><pub-id pub-id-type="pmcid">PMC7709221</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>W</given-names></name></person-group><article-title>New development in CAR-T cell therapy</article-title><source>J Hematol Oncol</source><year>2017</year><volume>10</volume><issue>1</issue><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s13045-017-0423-1</pub-id><pub-id pub-id-type="pmid">28222796</pub-id><pub-id pub-id-type="pmcid">PMC5320663</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yi</surname><given-names>M</given-names></name><name name-style="western"><surname>Qin</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name></person-group><article-title>Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>125</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-1057-4</pub-id><pub-id pub-id-type="pmid">31429760</pub-id><pub-id pub-id-type="pmcid">PMC6701025</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novak</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Darce</surname><given-names>JR</given-names></name><name name-style="western"><surname>Arendt</surname><given-names>BK</given-names></name><name name-style="western"><surname>Harder</surname><given-names>B</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>K</given-names></name><name name-style="western"><surname>Kindsvogel</surname><given-names>W</given-names></name><name name-style="western"><surname>Gross</surname><given-names>JA</given-names></name><name name-style="western"><surname>Greipp</surname><given-names>PR</given-names></name><name name-style="western"><surname>Jelinek</surname><given-names>DF</given-names></name></person-group><article-title>Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival</article-title><source>Blood</source><year>2004</year><volume>103</volume><issue>2</issue><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-06-2043</pub-id><pub-id pub-id-type="pmid">14512299</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>BCMA-targeted immunotherapy for multiple myeloma</article-title><source>J Hematol Oncol</source><year>2020</year><volume>13</volume><issue>1</issue><fpage>125</fpage><pub-id pub-id-type="doi">10.1186/s13045-020-00962-7</pub-id><pub-id pub-id-type="pmid">32943087</pub-id><pub-id pub-id-type="pmcid">PMC7499842</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roex</surname><given-names>G</given-names></name><name name-style="western"><surname>Timmers</surname><given-names>M</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>K</given-names></name><name name-style="western"><surname>Campillo-Davo</surname><given-names>D</given-names></name><name name-style="western"><surname>Flumens</surname><given-names>D</given-names></name><name name-style="western"><surname>Schroyens</surname><given-names>W</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Berneman</surname><given-names>ZN</given-names></name><name name-style="western"><surname>Lion</surname><given-names>E</given-names></name><name name-style="western"><surname>Luo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma</article-title><source>J Hematol Oncol</source><year>2020</year><volume>13</volume><issue>1</issue><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/s13045-020-01001-1</pub-id><pub-id pub-id-type="pmid">33272302</pub-id><pub-id pub-id-type="pmcid">PMC7713173</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carpenter</surname><given-names>RO</given-names></name><name name-style="western"><surname>Evbuomwan</surname><given-names>MO</given-names></name><name name-style="western"><surname>Pittaluga</surname><given-names>S</given-names></name><name name-style="western"><surname>Rose</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Raffeld</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Gress</surname><given-names>RE</given-names></name><name name-style="western"><surname>Hakim</surname><given-names>FT</given-names></name><name name-style="western"><surname>Kochenderfer</surname><given-names>JN</given-names></name></person-group><article-title>B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><issue>8</issue><fpage>2048</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2422</pub-id><pub-id pub-id-type="pmid">23344265</pub-id><pub-id pub-id-type="pmcid">PMC3630268</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B-Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y-X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X-M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y-L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F-X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P-Y</given-names></name><name name-style="western"><surname>Lei</surname><given-names>B</given-names></name><etal/></person-group><article-title>Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM)</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>579</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-124953</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>KM</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>TE</given-names></name><name name-style="western"><surname>Evans</surname><given-names>JW</given-names></name><name name-style="western"><surname>Horton</surname><given-names>HM</given-names></name><name name-style="western"><surname>Latimer</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>SL</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>RA</given-names></name></person-group><article-title>Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells</article-title><source>Hum Gene Ther</source><year>2018</year><volume>29</volume><issue>5</issue><fpage>585</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1089/hum.2018.001</pub-id><pub-id pub-id-type="pmid">29641319</pub-id><pub-id pub-id-type="pmcid">PMC5930946</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Raje</surname><given-names>NS</given-names></name><name name-style="western"><surname>Berdeja</surname><given-names>JG</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>DS</given-names></name><name name-style="western"><surname>Jagannath</surname><given-names>S</given-names></name><name name-style="western"><surname>Madduri</surname><given-names>D</given-names></name><name name-style="western"><surname>Liedtke</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosenblatt</surname><given-names>J</given-names></name><name name-style="western"><surname>Maus</surname><given-names>MV</given-names></name><name name-style="western"><surname>Massaro</surname><given-names>M</given-names></name><etal/></person-group><article-title>Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>26</fpage><lpage>27</lpage></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timmers</surname><given-names>M</given-names></name><name name-style="western"><surname>Roex</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Campillo-Davo</surname><given-names>D</given-names></name><name name-style="western"><surname>Van Tendeloo</surname><given-names>VFI</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Berneman</surname><given-names>ZN</given-names></name><name name-style="western"><surname>Luo</surname><given-names>F</given-names></name><name name-style="western"><surname>Van Acker</surname><given-names>HH</given-names></name><name name-style="western"><surname>Anguille</surname><given-names>S</given-names></name></person-group><article-title>Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1613</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01613</pub-id><pub-id pub-id-type="pmid">31379824</pub-id><pub-id pub-id-type="pmcid">PMC6646459</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>R</given-names></name><name name-style="western"><surname>Al-Khadairi</surname><given-names>G</given-names></name><name name-style="western"><surname>Roelands</surname><given-names>J</given-names></name><name name-style="western"><surname>Hendrickx</surname><given-names>W</given-names></name><name name-style="western"><surname>Dermime</surname><given-names>S</given-names></name><name name-style="western"><surname>Bedognetti</surname><given-names>D</given-names></name><name name-style="western"><surname>Decock</surname><given-names>J</given-names></name></person-group><article-title>NY-ESO-1 based immunotherapy of cancer: current perspectives</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>947</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00947</pub-id><pub-id pub-id-type="pmid">29770138</pub-id><pub-id pub-id-type="pmcid">PMC5941317</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rapoport</surname><given-names>A</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Blouch</surname><given-names>K</given-names></name><name name-style="western"><surname>Butler</surname><given-names>E</given-names></name><name name-style="western"><surname>Deyoung</surname><given-names>MP</given-names></name><name name-style="western"><surname>Farsaci</surname><given-names>B</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>AN</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>AP</given-names></name><name name-style="western"><surname>Huff</surname><given-names>A</given-names></name><etal/></person-group><article-title>Open-label pilot study of genetically engineered NY-ESO-1&#8211;specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>15_suppl</issue><fpage>TPS8555</fpage><lpage>TPS8555</lpage><pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.TPS8555</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N</given-names></name><name name-style="western"><surname>Qi</surname><given-names>W</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><name name-style="western"><surname>Lou</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma</article-title><source>Biomark Res</source><year>2020</year><volume>8</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s40364-020-00192-6</pub-id><pub-id pub-id-type="pmid">32435496</pub-id><pub-id pub-id-type="pmcid">PMC7222432</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>C</given-names></name><name name-style="western"><surname>Jozwik</surname><given-names>A</given-names></name><name name-style="western"><surname>Pepper</surname><given-names>A</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>R</given-names></name></person-group><article-title>Allogeneic CAR-T cells: More than ease of access?</article-title><source>Cells</source><year>2018</year><volume>7</volume><issue>10</issue><fpage>155</fpage><pub-id pub-id-type="doi">10.3390/cells7100155</pub-id><pub-id pub-id-type="pmcid">PMC6210057</pub-id><pub-id pub-id-type="pmid">30275435</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>Engineering switchable and programmable universal CARs for CAR T therapy</article-title><source>J Hematol Oncol</source><year>2019</year><volume>12</volume><issue>1</issue><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s13045-019-0763-0</pub-id><pub-id pub-id-type="pmid">31272471</pub-id><pub-id pub-id-type="pmcid">PMC6610960</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metelo</surname><given-names>AM</given-names></name><name name-style="western"><surname>Walker</surname><given-names>I</given-names></name><name name-style="western"><surname>Jozwik</surname><given-names>A</given-names></name><name name-style="western"><surname>Graham</surname><given-names>C</given-names></name><name name-style="western"><surname>Attwood</surname><given-names>C</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>K</given-names></name><name name-style="western"><surname>Dunlop</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuthill</surname><given-names>K</given-names></name><name name-style="western"><surname>Rice</surname><given-names>C</given-names></name><name name-style="western"><surname>Streetly</surname><given-names>M</given-names></name><etal/></person-group><article-title>Allogeneic anti-Bcma CAR-T cells show tumour specific killing against primary multiple myeloma cells from different genomic sub-groups</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>1834</fpage><lpage>1834</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-124312</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>AL</given-names></name><name name-style="western"><surname>He</surname><given-names>QF</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Sha</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Lu</surname><given-names>XJ</given-names></name></person-group><article-title>Applications and advances of CRISPR-Cas9 in cancer immunotherapy</article-title><source>J Med Genet</source><year>2019</year><volume>56</volume><issue>1</issue><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2018-105422</pub-id><pub-id pub-id-type="pmid">29970486</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachanova</surname><given-names>V</given-names></name><name name-style="western"><surname>Maakaron</surname><given-names>J</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>DH</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q</given-names></name><name name-style="western"><surname>DeFor</surname><given-names>TE</given-names></name><name name-style="western"><surname>He</surname><given-names>F</given-names></name><name name-style="western"><surname>Janakiram</surname><given-names>M</given-names></name><name name-style="western"><surname>Wangen</surname><given-names>R</given-names></name><name name-style="western"><surname>Cayci</surname><given-names>Z</given-names></name><name name-style="western"><surname>Grzywacz</surname><given-names>B</given-names></name><etal/></person-group><article-title>Results of a phase 1 trial of Gda-201, nicotinamide-expanded allogeneic natural killer (NK) Cells in patients with refractory non-hodgkin lymphoma (NHL) and multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>6</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-142419</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topp</surname><given-names>MS</given-names></name><name name-style="western"><surname>G&#246;kbuget</surname><given-names>N</given-names></name><name name-style="western"><surname>Zugmaier</surname><given-names>G</given-names></name><name name-style="western"><surname>Klappers</surname><given-names>P</given-names></name><name name-style="western"><surname>Stelljes</surname><given-names>M</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>S</given-names></name><name name-style="western"><surname>Viardot</surname><given-names>A</given-names></name><name name-style="western"><surname>Marks</surname><given-names>R</given-names></name><name name-style="western"><surname>Diedrich</surname><given-names>H</given-names></name><name name-style="western"><surname>Faul</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><issue>36</issue><fpage>4134</fpage><lpage>4140</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.56.3247</pub-id><pub-id pub-id-type="pmid">25385737</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkmann</surname><given-names>U</given-names></name><name name-style="western"><surname>Kontermann</surname><given-names>RE</given-names></name></person-group><article-title>The making of bispecific antibodies</article-title><source>MAbs</source><year>2017</year><volume>9</volume><issue>2</issue><fpage>182</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1080/19420862.2016.1268307</pub-id><pub-id pub-id-type="pmid">28071970</pub-id><pub-id pub-id-type="pmcid">PMC5297537</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Chari</surname><given-names>A</given-names></name><name name-style="western"><surname>Scott</surname><given-names>E</given-names></name><name name-style="western"><surname>Mezzi</surname><given-names>K</given-names></name><name name-style="western"><surname>Usmani</surname><given-names>SZ</given-names></name></person-group><article-title>B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches</article-title><source>Leukemia</source><year>2020</year><volume>34</volume><issue>4</issue><fpage>985</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-0734-z</pub-id><pub-id pub-id-type="pmid">32055000</pub-id><pub-id pub-id-type="pmcid">PMC7214244</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trudel</surname><given-names>S</given-names></name><name name-style="western"><surname>Lendvai</surname><given-names>N</given-names></name><name name-style="western"><surname>Popat</surname><given-names>R</given-names></name><name name-style="western"><surname>Voorhees</surname><given-names>PM</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>B</given-names></name><name name-style="western"><surname>Libby</surname><given-names>EN</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>PG</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>LD</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Yong</surname><given-names>K</given-names></name><etal/></person-group><article-title>Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial</article-title><source>Lancet Oncol</source><year>2018</year><volume>19</volume><issue>12</issue><fpage>1641</fpage><lpage>1653</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30576-X</pub-id><pub-id pub-id-type="pmid">30442502</pub-id><pub-id pub-id-type="pmcid">PMC6328058</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherbenou</surname><given-names>DW</given-names></name><name name-style="western"><surname>Aftab</surname><given-names>BT</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>CR</given-names></name><name name-style="western"><surname>Wiita</surname><given-names>A</given-names></name><name name-style="western"><surname>Logan</surname><given-names>AC</given-names></name><name name-style="western"><surname>Acosta-Alvear</surname><given-names>D</given-names></name><name name-style="western"><surname>Hann</surname><given-names>BC</given-names></name><name name-style="western"><surname>Walter</surname><given-names>P</given-names></name><name name-style="western"><surname>Shuman</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells</article-title><source>J Clin Investig</source><year>2016</year><volume>126</volume><issue>12</issue><fpage>4640</fpage><lpage>4653</lpage><pub-id pub-id-type="doi">10.1172/JCI85856</pub-id><pub-id pub-id-type="pmid">27841764</pub-id><pub-id pub-id-type="pmcid">PMC5127683</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seckinger</surname><given-names>A</given-names></name><name name-style="western"><surname>Delgado</surname><given-names>JA</given-names></name><name name-style="western"><surname>Moser</surname><given-names>S</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>L</given-names></name><name name-style="western"><surname>Neuber</surname><given-names>B</given-names></name><name name-style="western"><surname>Grab</surname><given-names>A</given-names></name><name name-style="western"><surname>Lipp</surname><given-names>S</given-names></name><name name-style="western"><surname>Merino</surname><given-names>J</given-names></name><name name-style="western"><surname>Prosper</surname><given-names>F</given-names></name><name name-style="western"><surname>Emde</surname><given-names>M</given-names></name><etal/></person-group><article-title>Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment</article-title><source>Cancer Cell</source><year>2017</year><volume>31</volume><issue>3</issue><fpage>396</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.02.002</pub-id><pub-id pub-id-type="pmid">28262554</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>EL</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>K</given-names></name><name name-style="western"><surname>Staehr</surname><given-names>M</given-names></name><name name-style="western"><surname>Masakayan</surname><given-names>R</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J</given-names></name><name name-style="western"><surname>Long</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Ng</surname><given-names>KY</given-names></name><name name-style="western"><surname>Ghoddusi</surname><given-names>M</given-names></name><name name-style="western"><surname>Purdon</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells</article-title><source>Sci Transl Med</source><year>2019</year><volume>11</volume><issue>485</issue><fpage>eaau7746</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aau7746</pub-id><pub-id pub-id-type="pmid">30918115</pub-id><pub-id pub-id-type="pmcid">PMC7508042</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ovacik</surname><given-names>AM</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Lemper</surname><given-names>M</given-names></name><name name-style="western"><surname>Danilenko</surname><given-names>D</given-names></name><name name-style="western"><surname>Stagg</surname><given-names>N</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>M</given-names></name><name name-style="western"><surname>Ellerman</surname><given-names>D</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V</given-names></name><name name-style="western"><surname>Kalia</surname><given-names>N</given-names></name><name name-style="western"><surname>Nguy</surname><given-names>T</given-names></name><etal/></person-group><article-title>Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties</article-title><source>MAbs</source><year>2019</year><volume>11</volume><issue>2</issue><fpage>422</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1080/19420862.2018.1551676</pub-id><pub-id pub-id-type="pmid">30550367</pub-id><pub-id pub-id-type="pmcid">PMC6380433</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>A</given-names></name><name name-style="western"><surname>Goetsch</surname><given-names>L</given-names></name><name name-style="western"><surname>Dumontet</surname><given-names>C</given-names></name><name name-style="western"><surname>Corva&#239;a</surname><given-names>N</given-names></name></person-group><article-title>Strategies and challenges for the next generation of antibody-drug conjugates</article-title><source>Nat Rev Drug Discov</source><year>2017</year><volume>16</volume><issue>5</issue><fpage>315</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.268</pub-id><pub-id pub-id-type="pmid">28303026</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma</article-title><source>J Hematol Oncol</source><year>2019</year><volume>12</volume><issue>1</issue><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/s13045-019-0786-6</pub-id><pub-id pub-id-type="pmid">31500657</pub-id><pub-id pub-id-type="pmcid">PMC6734251</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>D</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AV</given-names></name><name name-style="western"><surname>Brahmandam</surname><given-names>M</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>R</given-names></name><name name-style="western"><surname>Bandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hideshima</surname><given-names>T</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>G</given-names></name><name name-style="western"><surname>Podar</surname><given-names>K</given-names></name><name name-style="western"><surname>Tai</surname><given-names>YT</given-names></name><name name-style="western"><surname>Mitsiades</surname><given-names>C</given-names></name><etal/></person-group><article-title>Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target</article-title><source>Cancer Cell</source><year>2009</year><volume>16</volume><issue>4</issue><fpage>309</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.08.019</pub-id><pub-id pub-id-type="pmid">19800576</pub-id><pub-id pub-id-type="pmcid">PMC2762396</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Cornelison</surname><given-names>GL</given-names></name><name name-style="western"><surname>Howard</surname><given-names>C</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>GL</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Willert</surname><given-names>EK</given-names></name></person-group><article-title>Abstract 539: novel engineered toxin bodies targeting SLAMF7 (CS1)</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>539</fpage><lpage>539</lpage></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>PG</given-names></name><name name-style="western"><surname>Htut</surname><given-names>M</given-names></name><name name-style="western"><surname>Gasparetto</surname><given-names>C</given-names></name><name name-style="western"><surname>Zonder</surname><given-names>JA</given-names></name><name name-style="western"><surname>Martin</surname><given-names>TG</given-names><suffix>III</suffix></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>C</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>P</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>N</given-names></name><name name-style="western"><surname>Wysowskyj</surname><given-names>H</given-names></name><etal/></person-group><article-title>Results from phase 1/2 trial of tagraxofusp in combination with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>3145</fpage><lpage>3145</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-130410</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pemmaraju</surname><given-names>N</given-names></name><name name-style="western"><surname>Lane</surname><given-names>AA</given-names></name><name name-style="western"><surname>Sweet</surname><given-names>KL</given-names></name><name name-style="western"><surname>Stein</surname><given-names>AS</given-names></name><name name-style="western"><surname>Vasu</surname><given-names>S</given-names></name><name name-style="western"><surname>Blum</surname><given-names>W</given-names></name><name name-style="western"><surname>Rizzieri</surname><given-names>DA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>ES</given-names></name><name name-style="western"><surname>Duvic</surname><given-names>M</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><issue>17</issue><fpage>1628</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1815105</pub-id><pub-id pub-id-type="pmid">31018069</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strassz</surname><given-names>A</given-names></name><name name-style="western"><surname>Raab</surname><given-names>MS</given-names></name><name name-style="western"><surname>Orlowski</surname><given-names>RZ</given-names></name><name name-style="western"><surname>Kulke</surname><given-names>M</given-names></name><name name-style="western"><surname>Schiedner</surname><given-names>G</given-names></name><name name-style="western"><surname>Pahl</surname><given-names>A</given-names></name></person-group><article-title>A first in human study planned to evaluate Hdp-101, an anti-BCMA amanitin antibody-drug conjugate with a new payload and a new mode of action, in multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>34</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-142285</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pahl</surname><given-names>A</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>C</given-names></name><name name-style="western"><surname>Hechler</surname><given-names>T</given-names></name></person-group><article-title>Amanitins and their development as a payload for antibody-drug conjugates</article-title><source>Drug Discov Today Technol</source><year>2018</year><volume>30</volume><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2018.08.005</pub-id><pub-id pub-id-type="pmid">30553524</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figueroa-Vazquez</surname><given-names>V</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J</given-names></name><name name-style="western"><surname>Breunig</surname><given-names>C</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>A</given-names></name><name name-style="western"><surname>Giesen</surname><given-names>N</given-names></name><name name-style="western"><surname>P&#225;lfi</surname><given-names>A</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>C</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>C</given-names></name><name name-style="western"><surname>Hechler</surname><given-names>T</given-names></name><name name-style="western"><surname>Kulke</surname><given-names>M</given-names></name><etal/></person-group><article-title>HDP-101, anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells</article-title><source>Mol Cancer Ther</source><year>2020</year><volume>20</volume><fpage>367</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-20-0287</pub-id><pub-id pub-id-type="pmid">33298585</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateos</surname><given-names>MV</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>MA</given-names></name><name name-style="western"><surname>Cavo</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Jakubowiak</surname><given-names>A</given-names></name><name name-style="western"><surname>Knop</surname><given-names>S</given-names></name><name name-style="western"><surname>Doyen</surname><given-names>C</given-names></name><name name-style="western"><surname>Lucio</surname><given-names>P</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><issue>6</issue><fpage>518</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1714678</pub-id><pub-id pub-id-type="pmid">29231133</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedyk</surname><given-names>ER</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Koch</surname><given-names>A</given-names></name><name name-style="western"><surname>Smithson</surname><given-names>G</given-names></name><name name-style="western"><surname>Estevam</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Lahu</surname><given-names>G</given-names></name><name name-style="western"><surname>Roepcke</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Mclean</surname><given-names>L</given-names></name></person-group><article-title>Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects</article-title><source>Br J Clin Pharmacol</source><year>2020</year><volume>86</volume><issue>7</issue><fpage>1314</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1111/bcp.14241</pub-id><pub-id pub-id-type="pmid">32045493</pub-id><pub-id pub-id-type="pmcid">PMC7319013</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matlung</surname><given-names>HL</given-names></name><name name-style="western"><surname>Szilagyi</surname><given-names>K</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>NA</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>TK</given-names></name></person-group><article-title>The CD47-SIRP&#945; signaling axis as an innate immune checkpoint in cancer</article-title><source>Immunol Rev</source><year>2017</year><volume>276</volume><issue>1</issue><fpage>145</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1111/imr.12527</pub-id><pub-id pub-id-type="pmid">28258703</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>J</given-names></name><name name-style="western"><surname>Bouchlaka</surname><given-names>MN</given-names></name><name name-style="western"><surname>Puro</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Capoccia</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Hiebsch</surname><given-names>RR</given-names></name><name name-style="western"><surname>Donio</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>WC</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>P</given-names></name><name name-style="western"><surname>Sung</surname><given-names>V</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>DS</given-names></name></person-group><article-title>Highly differentiated anti-CD47 antibody, AO-176, potently inhibits hematologic malignancies alone and in combination</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>1844</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-126298</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>WC</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J</given-names></name><name name-style="western"><surname>Puro</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Andrejeva</surname><given-names>G</given-names></name><name name-style="western"><surname>Capoccia</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Donio</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hiebsch</surname><given-names>RR</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>P</given-names></name><name name-style="western"><surname>Sung</surname><given-names>V</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>DS</given-names></name></person-group><article-title>AO-176, a highly differentiated clinical stage anti-CD47 antibody, exerts potent anti-tumor activity in preclinical models of multiple myeloma as a single agent and in combination with approved therapeutics</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>3</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-139655</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chari</surname><given-names>A</given-names></name><name name-style="western"><surname>Vogl</surname><given-names>DT</given-names></name><name name-style="western"><surname>Gavriatopoulou</surname><given-names>M</given-names></name><name name-style="western"><surname>Nooka</surname><given-names>AK</given-names></name><name name-style="western"><surname>Yee</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Huff</surname><given-names>CA</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Dingli</surname><given-names>D</given-names></name><name name-style="western"><surname>Cole</surname><given-names>C</given-names></name><name name-style="western"><surname>Lonial</surname><given-names>S</given-names></name><etal/></person-group><article-title>Oral selinexor-dexamethasone for triple-class refractory multiple myeloma</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>8</issue><fpage>727</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1903455</pub-id><pub-id pub-id-type="pmid">31433920</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gasparetto</surname><given-names>C</given-names></name><name name-style="western"><surname>Mikhael</surname><given-names>J</given-names></name><name name-style="western"><surname>Vij</surname><given-names>R</given-names></name><name name-style="western"><surname>Pegourie</surname><given-names>B</given-names></name><name name-style="western"><surname>Benboubker</surname><given-names>L</given-names></name><name name-style="western"><surname>Facon</surname><given-names>T</given-names></name><name name-style="western"><surname>Amiot</surname><given-names>M</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma</article-title><source>Blood</source><year>2017</year><volume>130</volume><issue>22</issue><fpage>2401</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-06-788786</pub-id><pub-id pub-id-type="pmid">29018077</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Chanan-Khan</surname><given-names>A</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>AW</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>AB</given-names></name><name name-style="western"><surname>Facon</surname><given-names>T</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Touzeau</surname><given-names>C</given-names></name><name name-style="western"><surname>Punnoose</surname><given-names>EA</given-names></name><name name-style="western"><surname>Cordero</surname><given-names>J</given-names></name><name name-style="western"><surname>Munasinghe</surname><given-names>W</given-names></name><etal/></person-group><article-title>Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM</article-title><source>Blood</source><year>2017</year><volume>130</volume><issue>22</issue><fpage>2392</fpage><lpage>2400</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-06-788323</pub-id><pub-id pub-id-type="pmid">28847998</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>SK</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Cavo</surname><given-names>M</given-names></name><name name-style="western"><surname>de la Rubia</surname><given-names>J</given-names></name><name name-style="western"><surname>Popat</surname><given-names>R</given-names></name><name name-style="western"><surname>Gasparetto</surname><given-names>C</given-names></name><name name-style="western"><surname>Hungria</surname><given-names>V</given-names></name><name name-style="western"><surname>Salwender</surname><given-names>H</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I</given-names></name><etal/></person-group><article-title>Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><issue>12</issue><fpage>1630</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30525-8</pub-id><pub-id pub-id-type="pmid">33129376</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Baz</surname><given-names>RC</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Quach</surname><given-names>H</given-names></name><name name-style="western"><surname>Ho</surname><given-names>S-J</given-names></name><name name-style="western"><surname>Vangsted</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>SD</given-names></name><name name-style="western"><surname>Salem</surname><given-names>AH</given-names></name><name name-style="western"><surname>Coppola</surname><given-names>S</given-names></name><etal/></person-group><article-title>Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>15_suppl</issue><fpage>8511</fpage><lpage>8511</lpage><pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.8511</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Bai</surname><given-names>L</given-names></name></person-group><article-title>MCL-1 inhibition in cancer treatment</article-title><source>Onco Targets Ther</source><year>2018</year><volume>11</volume><fpage>7301</fpage><lpage>7314</lpage><pub-id pub-id-type="doi">10.2147/OTT.S146228</pub-id><pub-id pub-id-type="pmid">30425521</pub-id><pub-id pub-id-type="pmcid">PMC6205821</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caenepeel</surname><given-names>S</given-names></name><name name-style="western"><surname>Karen</surname><given-names>R</given-names></name><name name-style="western"><surname>Belmontes</surname><given-names>B</given-names></name><name name-style="western"><surname>Verlinsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wahlstrom</surname><given-names>J</given-names></name><etal/></person-group><article-title>Abstract 6218: Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>6218</fpage><lpage>6218</lpage></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Abstract 73: development of APG-3526 as a novel and highly efficacious MCL-1 inhibitor</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>73</fpage><lpage>73</lpage></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>San-Miguel</surname><given-names>JF</given-names></name><name name-style="western"><surname>Hungria</surname><given-names>VT</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SS</given-names></name><name name-style="western"><surname>Beksac</surname><given-names>M</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>MA</given-names></name><name name-style="western"><surname>Elghandour</surname><given-names>A</given-names></name><name name-style="western"><surname>Jedrzejczak</surname><given-names>WW</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>A</given-names></name><name name-style="western"><surname>Nakorn</surname><given-names>TN</given-names></name><name name-style="western"><surname>Siritanaratkul</surname><given-names>N</given-names></name><etal/></person-group><article-title>Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>11</issue><fpage>1195</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70440-1</pub-id><pub-id pub-id-type="pmid">25242045</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cengiz Seval</surname><given-names>G</given-names></name><name name-style="western"><surname>Beksac</surname><given-names>M</given-names></name></person-group><article-title>A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma</article-title><source>Expert Opin Drug Saf</source><year>2019</year><volume>18</volume><issue>7</issue><fpage>563</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1080/14740338.2019.1615051</pub-id><pub-id pub-id-type="pmid">31070945</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>H</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>DH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KP</given-names></name><name name-style="western"><surname>Bae</surname><given-names>KS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WS</given-names></name><name name-style="western"><surname>Eom</surname><given-names>HS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hong</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><etal/></person-group><article-title>Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy</article-title><source>Investig New Drugs</source><year>2018</year><volume>36</volume><issue>5</issue><fpage>877</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1007/s10637-018-0582-0</pub-id><pub-id pub-id-type="pmid">29520651</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jia</surname><given-names>B</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China</article-title><source>J Hematol Oncol</source><year>2017</year><volume>10</volume><issue>1</issue><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s13045-017-0439-6</pub-id><pub-id pub-id-type="pmid">28298231</pub-id><pub-id pub-id-type="pmcid">PMC5351273</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>XG</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YR</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>HW</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>XY</given-names></name></person-group><article-title>Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner</article-title><source>Oncol Lett</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">31289512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2019.10301</pub-id><pub-id pub-id-type="pmcid">PMC6540238</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivanandhan</surname><given-names>D</given-names></name><name name-style="western"><surname>Rajagopal</surname><given-names>S</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S</given-names></name><name name-style="western"><surname>Basavaprabhu</surname><given-names>B</given-names></name><name name-style="western"><surname>Dhkar</surname><given-names>R</given-names></name><name name-style="western"><surname>Viswakarma</surname><given-names>S</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>A</given-names></name><name name-style="western"><surname>Zainuddin</surname><given-names>M</given-names></name><name name-style="western"><surname>Rudresh</surname><given-names>G</given-names></name><name name-style="western"><surname>Daram</surname><given-names>P</given-names></name><etal/></person-group><article-title>Abstract 1756: JBI-802 novel dual inhibitor of LSD1-HDAC6 for treatment of cancer</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>1756</fpage><lpage>1756</lpage></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Abstract 513: preclinical evaluation of novel HDAC6 selective inhibitors CVL608 with potent <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> profiles in tumors</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>513</fpage><lpage>513</lpage></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Abstract 4441: CS3003, an HDAC6-selective inhibitor, improves anti-PD-1 immune checkpoint blockade therapy efficacy</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>4441</fpage><lpage>4441</lpage></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamberlain</surname><given-names>PP</given-names></name><name name-style="western"><surname>Hamann</surname><given-names>LG</given-names></name></person-group><article-title>Development of targeted protein degradation therapeutics</article-title><source>Nat Chem Biol</source><year>2019</year><volume>15</volume><issue>10</issue><fpage>937</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1038/s41589-019-0362-y</pub-id><pub-id pub-id-type="pmid">31527835</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>Novel immunomodulatory drugs and neo-substrates</article-title><source>Biomark Res</source><year>2020</year><volume>8</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s40364-020-0182-y</pub-id><pub-id pub-id-type="pmid">31938543</pub-id><pub-id pub-id-type="pmcid">PMC6953231</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonial</surname><given-names>S</given-names></name><name name-style="western"><surname>Amatangelo</surname><given-names>M</given-names></name><name name-style="western"><surname>Popat</surname><given-names>R</given-names></name><name name-style="western"><surname>Minnema</surname><given-names>MC</given-names></name><name name-style="western"><surname>Zonder</surname><given-names>JA</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Oriol Rocafiguera</surname><given-names>A</given-names></name><name name-style="western"><surname>Campagnaro</surname><given-names>EL</given-names></name><name name-style="western"><surname>Rodriguez Otero</surname><given-names>P</given-names></name><name name-style="western"><surname>Badros</surname><given-names>AZ</given-names></name><etal/></person-group><article-title>Translational and clinical evidence of a differentiated profile for the novel CELMoD, iberdomide (CC-220)</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>Supplement_1</issue><fpage>3119</fpage><lpage>3119</lpage><pub-id pub-id-type="doi">10.1182/blood-2019-124298</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>C</given-names></name><name name-style="western"><surname>Liao</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Abstract 6367: KPG-818, a novel cereblon modulator, inhibits hematological malignancies in preclinical models</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>6367</fpage><lpage>6367</lpage></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chourasia</surname><given-names>AH</given-names></name><name name-style="western"><surname>Fung</surname><given-names>L</given-names></name><name name-style="western"><surname>Pasis</surname><given-names>A</given-names></name><name name-style="western"><surname>McElwee</surname><given-names>B</given-names></name><name name-style="western"><surname>Schoolmeesters</surname><given-names>A</given-names></name><name name-style="western"><surname>Richard</surname><given-names>N</given-names></name><name name-style="western"><surname>Lam</surname><given-names>I</given-names></name><name name-style="western"><surname>Torres</surname><given-names>E</given-names></name><name name-style="western"><surname>Erdman</surname><given-names>P</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>R</given-names></name><etal/></person-group><article-title>Abstract 1963: Targeting hematological malignancies with two functionally and mechanistically distinct classes of cereblon mediated protein homeostatic modulators</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>1963</fpage><lpage>1963</lpage></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heuck</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Jethava</surname><given-names>Y</given-names></name><name name-style="western"><surname>Khan</surname><given-names>R</given-names></name><name name-style="western"><surname>van Rhee</surname><given-names>F</given-names></name><name name-style="western"><surname>Zangari</surname><given-names>M</given-names></name><name name-style="western"><surname>Chavan</surname><given-names>S</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>K</given-names></name><name name-style="western"><surname>Miller</surname><given-names>SE</given-names></name><name name-style="western"><surname>Matin</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibiting MEK in MAPK pathway-activated myeloma</article-title><source>Leukemia</source><year>2016</year><volume>30</volume><issue>4</issue><fpage>976</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1038/leu.2015.208</pub-id><pub-id pub-id-type="pmid">26228812</pub-id><pub-id pub-id-type="pmcid">PMC4832073</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robiou du Pont</surname><given-names>S</given-names></name><name name-style="western"><surname>Cleynen</surname><given-names>A</given-names></name><name name-style="western"><surname>Fontan</surname><given-names>C</given-names></name><name name-style="western"><surname>Attal</surname><given-names>M</given-names></name><name name-style="western"><surname>Munshi</surname><given-names>N</given-names></name><name name-style="western"><surname>Corre</surname><given-names>J</given-names></name><name name-style="western"><surname>Avet-Loiseau</surname><given-names>H</given-names></name></person-group><article-title>Genomics of multiple myeloma</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>9</issue><fpage>963</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.70.6705</pub-id><pub-id pub-id-type="pmid">28297630</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Packiriswamy</surname><given-names>N</given-names></name><name name-style="western"><surname>Upreti</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Khan</surname><given-names>R</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>RM</given-names></name><name name-style="western"><surname>Rooney</surname><given-names>CM</given-names></name><name name-style="western"><surname>Dispenzieri</surname><given-names>A</given-names></name><name name-style="western"><surname>Peng</surname><given-names>KW</given-names></name><name name-style="western"><surname>Russell</surname><given-names>SJ</given-names></name></person-group><article-title>Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma</article-title><source>Leukemia</source><year>2020</year><volume>34</volume><fpage>3310</fpage><lpage>3322</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-0828-7</pub-id><pub-id pub-id-type="pmid">32327728</pub-id><pub-id pub-id-type="pmcid">PMC7581629</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>TT</given-names></name></person-group><article-title>NY-ESO-1 Protein vaccine combining alum, CpG ODN, and HH2 complex adjuvant induces protective and therapeutic anti-tumor responses in murine multiple myeloma</article-title><source>Onco Targets Ther</source><year>2020</year><volume>13</volume><fpage>8069</fpage><lpage>8077</lpage><pub-id pub-id-type="doi">10.2147/OTT.S255713</pub-id><pub-id pub-id-type="pmid">32884292</pub-id><pub-id pub-id-type="pmcid">PMC7431605</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>J</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name><name name-style="western"><surname>Daley</surname><given-names>J</given-names></name><name name-style="western"><surname>Tai</surname><given-names>YT</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>KC</given-names></name><name name-style="western"><surname>Munshi</surname><given-names>NC</given-names></name></person-group><article-title>A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma</article-title><source>Br J Haematol</source><year>2012</year><volume>157</volume><issue>6</issue><fpage>687</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2012.09111.x</pub-id><pub-id pub-id-type="pmid">22533610</pub-id><pub-id pub-id-type="pmcid">PMC3819168</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cook</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>K-W</given-names></name><name name-style="western"><surname>Ginos</surname><given-names>BF</given-names></name><name name-style="western"><surname>Dueck</surname><given-names>AC</given-names></name><name name-style="western"><surname>Giers</surname><given-names>M</given-names></name><name name-style="western"><surname>Packiriswamy</surname><given-names>N</given-names></name><name name-style="western"><surname>Brunton</surname><given-names>B</given-names></name><name name-style="western"><surname>Patnaik</surname><given-names>MM</given-names></name><name name-style="western"><surname>Witzig</surname><given-names>TE</given-names></name><name name-style="western"><surname>Buadi</surname><given-names>FK</given-names></name><etal/></person-group><article-title>Phase I trial of systemic administration of vesicular stomatitis virus genetically engineered to express NIS and human interferon beta, in patients with relapsed or refractory multiple myeloma (MM), acute myeloid leukemia (AML), and T-cell neoplasms (TCL)</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>7</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-140853</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perica</surname><given-names>K</given-names></name><name name-style="western"><surname>De Le&#243;n</surname><given-names>MA</given-names></name><name name-style="western"><surname>Durai</surname><given-names>M</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>YL</given-names></name><name name-style="western"><surname>Bieler</surname><given-names>JG</given-names></name><name name-style="western"><surname>Sibener</surname><given-names>L</given-names></name><name name-style="western"><surname>Niem&#246;ller</surname><given-names>M</given-names></name><name name-style="western"><surname>Assenmacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Richter</surname><given-names>A</given-names></name><name name-style="western"><surname>Edidin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nanoscale artificial antigen presenting cells for T cell immunotherapy</article-title><source>Nanomedicine</source><year>2014</year><volume>10</volume><issue>1</issue><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2013.06.015</pub-id><pub-id pub-id-type="pmid">23891987</pub-id><pub-id pub-id-type="pmcid">PMC4114774</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vallet</surname><given-names>S</given-names></name><name name-style="western"><surname>Pecherstorfer</surname><given-names>M</given-names></name><name name-style="western"><surname>Podar</surname><given-names>K</given-names></name></person-group><article-title>Adoptive cell therapy in multiple Myeloma</article-title><source>Expert Opin Biol Ther</source><year>2017</year><volume>17</volume><issue>12</issue><fpage>1511</fpage><lpage>1522</lpage><pub-id pub-id-type="doi">10.1080/14712598.2017.1375095</pub-id><pub-id pub-id-type="pmid">28857616</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodridge</surname><given-names>JP</given-names></name><name name-style="western"><surname>Bjordahl</surname><given-names>R</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>S</given-names></name><name name-style="western"><surname>Reiser</surname><given-names>J</given-names></name><name name-style="western"><surname>Gaidarova</surname><given-names>S</given-names></name><name name-style="western"><surname>Blum</surname><given-names>R</given-names></name><name name-style="western"><surname>Cichocki</surname><given-names>F</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Bonello</surname><given-names>G</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T</given-names></name><etal/></person-group><article-title>FT576: multi-specific off-the-shelf CAR-NK cell therapy engineered for enhanced persistence, avoidance of self-fratricide and optimized mab combination therapy to prevent antigenic escape and elicit a deep and durable response in multiple myeloma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>Supplement 1</issue><fpage>4</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-142750</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>WJ</given-names></name></person-group><article-title>The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma</article-title><source>Onco Targets Ther</source><year>2015</year><volume>8</volume><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.2147/OTT.S81022</pub-id><pub-id pub-id-type="pmid">25914547</pub-id><pub-id pub-id-type="pmcid">PMC4399549</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivaraj</surname><given-names>D</given-names></name><name name-style="western"><surname>Green</surname><given-names>MM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Long</surname><given-names>GD</given-names></name><name name-style="western"><surname>Rizzieri</surname><given-names>DA</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>AH</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>JL</given-names></name><name name-style="western"><surname>Chao</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Gasparetto</surname><given-names>C</given-names></name></person-group><article-title>Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma</article-title><source>Blood Cancer J</source><year>2018</year><volume>8</volume><issue>8</issue><fpage>71</fpage><pub-id pub-id-type="doi">10.1038/s41408-018-0104-5</pub-id><pub-id pub-id-type="pmid">30065277</pub-id><pub-id pub-id-type="pmcid">PMC6068091</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldsmith</surname><given-names>SR</given-names></name><name name-style="western"><surname>Fiala</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wildes</surname><given-names>TM</given-names></name><name name-style="western"><surname>Ghobadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Stockerl-Goldstein</surname><given-names>K</given-names></name><name name-style="western"><surname>Vij</surname><given-names>R</given-names></name></person-group><article-title>DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma</article-title><source>Ann Hematol</source><year>2020</year><volume>99</volume><issue>5</issue><fpage>1041</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1007/s00277-020-03970-2</pub-id><pub-id pub-id-type="pmid">32130471</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhutani</surname><given-names>D</given-names></name><name name-style="western"><surname>Raza</surname><given-names>S</given-names></name><name name-style="western"><surname>Assal</surname><given-names>A</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>A</given-names></name><name name-style="western"><surname>Mapara</surname><given-names>M</given-names></name><name name-style="western"><surname>Lentzsch</surname><given-names>S</given-names></name></person-group><article-title>Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma</article-title><source>Blood Cancer J</source><year>2020</year><volume>10</volume><issue>2</issue><fpage>13</fpage><pub-id pub-id-type="doi">10.1038/s41408-020-0278-5</pub-id><pub-id pub-id-type="pmid">32015343</pub-id><pub-id pub-id-type="pmcid">PMC6997347</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Steinhardt</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Grathwohl</surname><given-names>D</given-names></name><name name-style="western"><surname>Meckel</surname><given-names>K</given-names></name><name name-style="western"><surname>Nickel</surname><given-names>K</given-names></name><name name-style="western"><surname>Leicht</surname><given-names>HB</given-names></name><name name-style="western"><surname>Krummenast</surname><given-names>F</given-names></name><name name-style="western"><surname>Einsele</surname><given-names>H</given-names></name><name name-style="western"><surname>Rasche</surname><given-names>L</given-names></name><name name-style="western"><surname>Kort&#252;m</surname><given-names>KM</given-names></name></person-group><article-title>Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma</article-title><source>Cancer Med</source><year>2020</year><volume>9</volume><fpage>5819</fpage><lpage>5826</lpage><pub-id pub-id-type="doi">10.1002/cam4.3209</pub-id><pub-id pub-id-type="pmid">32608149</pub-id><pub-id pub-id-type="pmcid">PMC7433809</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wickstr&#246;m</surname><given-names>M</given-names></name><name name-style="western"><surname>Nygren</surname><given-names>P</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>R</given-names></name><name name-style="western"><surname>Harmenberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Sj&#246;berg</surname><given-names>P</given-names></name><name name-style="western"><surname>Jerling</surname><given-names>M</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>P</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Melflufen&#8212;a peptidase-potentiated alkylating agent in clinical trials</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>39</issue><fpage>66641</fpage><lpage>66655</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18420</pub-id><pub-id pub-id-type="pmid">29029544</pub-id><pub-id pub-id-type="pmcid">PMC5630444</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slipicevic</surname><given-names>A</given-names></name><name name-style="western"><surname>Munawar</surname><given-names>U</given-names></name><name name-style="western"><surname>St&#252;hmer</surname><given-names>T</given-names></name><name name-style="western"><surname>Aschan</surname><given-names>J</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Nupponen</surname><given-names>NN</given-names></name><name name-style="western"><surname>Miettinen</surname><given-names>J</given-names></name><name name-style="western"><surname>Huppunen</surname><given-names>M-E</given-names></name><name name-style="western"><surname>Heckman</surname><given-names>CA</given-names></name><name name-style="western"><surname>Mateos</surname><given-names>M-V</given-names></name><etal/></person-group><article-title>Abstract 1843: melflufen efficacy in multiple myeloma with <italic toggle="yes">TP53</italic> aberrations</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16 Supplement</issue><fpage>1843</fpage><lpage>1843</lpage></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>PG</given-names></name><name name-style="western"><surname>Oriol</surname><given-names>A</given-names></name><name name-style="western"><surname>Larocca</surname><given-names>A</given-names></name><name name-style="western"><surname>Blad&#233;</surname><given-names>J</given-names></name><name name-style="western"><surname>Cavo</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodriguez-Otero</surname><given-names>P</given-names></name><name name-style="western"><surname>Leleu</surname><given-names>X</given-names></name><name name-style="western"><surname>Nadeem</surname><given-names>O</given-names></name><name name-style="western"><surname>Hiemenz</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hassoun</surname><given-names>H</given-names></name><etal/></person-group><article-title>Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><issue>7</issue><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.02259</pub-id><pub-id pub-id-type="pmid">33296242</pub-id><pub-id pub-id-type="pmcid">PMC8078327</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Heng</surname><given-names>HH</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Heng</surname><given-names>HH</given-names></name></person-group><article-title>Chapter 3&#8212;genome chaos and macrocellular evolution: how evolutionary cytogenetics unravels the mystery of cancer</article-title><source>genome chaos</source><year>2019</year><publisher-loc>Cambridge</publisher-loc><publisher-name>Academic Press</publisher-name><fpage>95</fpage><lpage>168</lpage></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>Z</given-names></name><name name-style="western"><surname>Alemara</surname><given-names>S</given-names></name><name name-style="western"><surname>Mackenzie</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Abdallah</surname><given-names>B</given-names></name><name name-style="western"><surname>Horne</surname><given-names>S</given-names></name><name name-style="western"><surname>Regan</surname><given-names>S</given-names></name><name name-style="western"><surname>Heng</surname><given-names>HH</given-names></name></person-group><article-title>Micronuclei and genome chaos: changing the system inheritance</article-title><source>Genes (Basel)</source><year>2019</year><volume>10</volume><issue>5</issue><fpage>366</fpage><pub-id pub-id-type="doi">10.3390/genes10050366</pub-id><pub-id pub-id-type="pmcid">PMC6562739</pub-id><pub-id pub-id-type="pmid">31086101</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>JK</given-names></name><name name-style="western"><surname>Muffly</surname><given-names>LS</given-names></name><name name-style="western"><surname>Spinner</surname><given-names>MA</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>JI</given-names></name><name name-style="western"><surname>Owens</surname><given-names>DK</given-names></name><name name-style="western"><surname>Goldhaber-Fiebert</surname><given-names>JD</given-names></name></person-group><article-title>Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><issue>24</issue><fpage>2105</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.02079</pub-id><pub-id pub-id-type="pmid">31157579</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>LD</given-names></name><name name-style="western"><surname>Oso</surname><given-names>SO</given-names></name><name name-style="western"><surname>Levine</surname><given-names>AD</given-names></name></person-group><article-title>Medical crowdfunding to access CAR T-cell therapy</article-title><source>Lancet Oncol</source><year>2019</year><volume>20</volume><issue>8</issue><fpage>1062</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30466-8</pub-id><pub-id pub-id-type="pmid">31486373</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>